Treatments for systemic sclerosis
Nemolizumab, a monoclonal antibody targeting IL-31, addresses the challenges of treating systemic sclerosis by inhibiting IL-31 signaling and reducing symptoms through tailored dosing, providing effective treatment for systemic sclerosis.
Patent Information
- Application Number
- PCT/IB2026/054598
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-13
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-19
AI Technical Summary
There is a need for novel therapeutic regimes to treat systemic sclerosis, a clinically heterogeneous connective tissue disorder characterized by immune activation, vascular damage, and fibrosis of the skin and major internal organs, which affects skin flexibility, causes chronic joint pain, inflammation, and can lead to organ involvement.
The use of nemolizumab, a humanized monoclonal antibody targeting the interleukin-31 receptor alpha chain, to inhibit IL-31 signaling, administered in specific doses based on subject weight and frequency, optionally combined with anti-inflammatory or immunosuppressive drugs, for treating systemic sclerosis.
Nemolizumab effectively treats systemic sclerosis by reducing skin thickening, joint pain, and organ involvement, improving flexibility and reducing inflammation, with dosing tailored to individual patient needs.
Smart Images

Figure IB2026054598_19112026_PF_FP_ABST
Abstract
Description
Atty. Dkt. No.: 105153-10021TREATMENTS FOR SYSTEMIC SCLEROSISCROSS-REFERENCE TO RELATED PATENT APPLICATIONS
[0001] This application claims priority under 35 U. S. C. § 119(e) to U. S. Provisional Application 63 / 804,769 filed May 13, 2025, the entire contents of which is incorporated herein by reference.BACKGROUND
[0002] The following discussion is provided to aid the reader in understanding the disclosure and is not admitted to describe or constitute prior art thereto.
[0003] Systemic sclerosis (SSc, also known as systemic scleroderma) is a clinically heterogeneous connective tissue disorder characterized by immune activation, vascular damage, and fibrosis of the skin and major internal organs. Systemic scleroderma affects the skin and may affect the tissues under it, including blood vessels and major organs, such as lungs, the gastrointestinal tract, heart, or kidneys. The skin thickening that accompanies systemic scleroderma can cause tightening so there is a loss of flexibility and ease of movement, especially in the fingers. Facial involvement is common and may be mild or it can reduce facial movements, including decreasing the mouth opening.
[0004] Scleroderma may cause chronic joint pain, inflammation, and swelling in muscles and joints. Most scleroderma patients also experience Raynaud’s phenomenon, an exaggerated response to ambient temperatures, making one sensitive to cold. Raynaud’s phenomenon causes the skin of the fingers to look white or blue with cold temperature exposure or emotional stress. Skin sores or ulcers can occur due to lack of good blood flow in some cases.
[0005] There remains a need to develop novel therapeutic regimes to treat patients with systemic sclerosis.
[0006] Nemolizumab is a humanized monoclonal antibody recognizing the interleukin (IL)-31 receptor alpha chain (IL-3 IRA). By binding to IL-3 IRA, nemolizumab inhibits the-1- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021binding of IL-31 to its receptor and therefore blocks any subsequent transduction of the IL-31 induced signal into the cell.SUMMARY
[0007] Provided herein are methods for treating systemic sclerosis using an anti-IL31Ra antibody, such as nemolizumab or its equivalent. The disclosed methods comprise administering doses of the antibody that may be the same or different in comparison to doses of nemolizumab used to treat other indications, such as atopic dermatitis and prurigo nodularis. Optionally, the doses may vary depending on the size / weight of the subject. The disclosure also provides pharmaceutical compositions for treating systemic sclerosis comprising nemolizumab.
[0008] In one aspect, the present disclosure provides methods for treating systemic sclerosis, comprising administering to a subject with systemic sclerosis (a) at least 30 mg and up to 90 mg of nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 120 mg of nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg. In another aspect, the present disclosure provides methods for treating systemic sclerosis, comprising administering to a subject with systemic sclerosis at least 30 mg and up 120 mg of nemolizumab or an equivalent thereof.
[0009] In some embodiments, the subject suffers from diffuse scleroderma or limited scleroderma. In some embodiments, the systemic sclerosis has been assigned a score of at least 15 on the modified Rodnan skin score (mRSS).
[0010] In some embodiments, the nemolizumab or the equivalent thereof is administered by an enteric, a topical, or a parenteral route. In some embodiments, the nemolizumab or the equivalent thereof is administered subcutaneously.
[0011] In some embodiments, the nemolizumab or the equivalent thereof is administered once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, once every eleven weeks, once every twelve weeks, once every thirteen weeks, once every fourteen weeks, or once every fifteen weeks.-2- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021For example, the nemolizumab or the equivalent thereof is administered once every four weeks or once every eight weeks.
[0012] In some embodiments, the subject is an adult. In some embodiments, the subject is a pediatric patient.
[0013] In some embodiments, the nemolizumab or equivalent thereof is administered according to a flat dosing regimen with or without a loading dose (i.e., a fixed dose during the treatment period). The loading dose can be about 60 mg to about 120 mg. In some embodiments, the loading dose is between 60mg and 120 mg (e.g., 60, 60.5, 61, 61.5, 62,62.5, 63, 63.5, 64, 64.5, 65, 65.5, 66, 66.5, 67, 67.5, 68, 68.5, 69, 69.5, 70, 70.5, 71, 71.5, 72,72.5, 73, 73.5, 74, 74.5, 75, 75.5, 76, 76.5, 77, 77.5, 78, 78.5, 79, 79.5, 80, 80.5, 81, 81.5, 82,82.5, 83, 83.5, 84, 84.5, 85, 85.5, 86, 86.5, 87, 87.5, 88, 88.5, 89, 89.5, 90, 90.5, 91, 91.5, 92,92.5, 93, 93.5, 94, 94.5, 95, 95.5, 96, 96.5, 97, 97.5, 98, 98.5, 99, 99.5, 100, 100.5, 101,101.5, 102, 102.5, 103, 103.5, 104, 104.5, 105, 105.5, 106, 106.5, 107, 107.5, 108, 108.5, 109, 109.5, 110, 110.5, 111, 111.5, 112, 112.5, 113, 113.5, 114, 114.5, 115, 115.5, 116,116.5, 117, 117.5, 118, 118.5, 119, 119.5, or 120 mg). In some embodiments, the loading dose is 60mg. In some embodiments, the loading dose is 120mg. In some embodiments, the nemolizumab or equivalent thereof is administered according to a tiered fixed dosing regimen with or without a loading dose (i.e., using body weight or age cutoffs to define patient strata that receive different flat doses). In some embodiments, the nemolizumab or equivalent thereof is administered according to bodyweight-based dosing (i.e., mg / kg). In some embodiments, the pharmaceutical composition is formulated for administration by a loading dose regimen.
[0014] In some embodiments, the subject is administered nemolizumab. In some embodiments, the subject is further administered an effective amount of an anti-inflammatory drug or an immunosuppressive drug. In some embodiments, the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID). In some embodiments, the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.-3- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0015] In another aspect the present disclosure provides uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of systemic sclerosis, wherein the medicament comprises a tiered fixed dosing based on body weight cutoffs dosage of nemolizumab or an equivalent thereof that is (a) at least 30 mg and up to 90 mg nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 120 mg nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg. In another aspect, the disclosure provides uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of systemic sclerosis, wherein the medicament comprises a dosage of nemolizumab or an equivalent thereof that is at least 30 mg and up to 120 mg nemolizumab or an equivalent thereof.
[0016] In some embodiments, the subject suffers from diffuse scleroderma or limited scleroderma. In some embodiments, the subject suffers from limited scleroderma and has been assigned a score of at least 8 on the modified Rodnan skin score (mRSS). In some embodiments, the subject suffers from diffuse scleroderma and has been assigned a score of at least 12 on the modified Rodnan skin score (mRSS). In some embodiments, the subject has been assigned a score of at least 15 on the modified Rodnan skin score (mRSS).
[0017] In some embodiments, the medicament is formulated for administration by a topical or parenteral route. In some embodiments, the medicament is formulated for subcutaneous administration.
[0018] In some embodiments, the medicament is formulated for administration once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once every eleven weeks.
[0019] In some embodiments, the subject is an adult. In some embodiments, the subject is a pediatric patient.
[0020] In some embodiments, the nemolizumab or equivalent thereof is administered according to a flat dosing regimen with or without a loading dose (i.e., a fixed dose during the treatment period). The loading dose can be about 60 mg to about 120 mg. In some-4- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021embodiments, the loading dose is between 60mg and 120 mg (e.g., 60, 60.5, 61, 61.5, 62,62.5, 63, 63.5, 64, 64.5, 65, 65.5, 66, 66.5, 67, 67.5, 68, 68.5, 69, 69.5, 70, 70.5, 71, 71.5, 72,72.5, 73, 73.5, 74, 74.5, 75, 75.5, 76, 76.5, 77, 77.5, 78, 78.5, 79, 79.5, 80, 80.5, 81, 81.5, 82,82.5, 83, 83.5, 84, 84.5, 85, 85.5, 86, 86.5, 87, 87.5, 88, 88.5, 89, 89.5, 90, 90.5, 91, 91.5, 92,92.5, 93, 93.5, 94, 94.5, 95, 95.5, 96, 96.5, 97, 97.5, 98, 98.5, 99, 99.5, 100, 100.5, 101,101.5, 102, 102.5, 103, 103.5, 104, 104.5, 105, 105.5, 106, 106.5, 107, 107.5, 108, 108.5, 109, 109.5, 110, 110.5, 111, 111.5, 112, 112.5, 113, 113.5, 114, 114.5, 115, 115.5, 116,116.5, 117, 117.5, 118, 118.5, 119, 119.5, or 120 mg). In some embodiments, the loading dose is 60mg. In some embodiments, the loading dose is 120mg. In some embodiments, the nemolizumab or equivalent thereof is administered according to a tiered fixed dosing regimen with or without a loading dose (i.e., using body weight or age cutoffs to define patient strata that receive different flat doses). In some embodiments, the nemolizumab or equivalent thereof is administered according to bodyweight-based dosing (i.e., mg / kg). In some embodiments, the pharmaceutical composition is formulated for administration by a loading dose regimen.
[0021] In some embodiments, the medicament comprises nemolizumab. In some embodiments, the medicament further comprises an anti-inflammatory drug or an immunosuppressive drug. In some embodiments, the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID). In some embodiments, the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.
[0022] In another aspect the present disclosure provides pharmaceutical compositions comprising nemolizumab or an equivalent thereof for treatment of systemic sclerosis, wherein the pharmaceutical composition comprises a dosage of nemolizumab or an equivalent thereof that is (a) at least 30 mg and up to 90 mg nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 120 mg nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg. In another aspect the present disclosure provides pharmaceutical compositions comprising nemolizumab or an equivalent thereof for treatment of systemic sclerosis, wherein the-5- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021pharmaceutical composition comprises a dosage of nemolizumab or an equivalent thereof that is at least 30 mg and up to 120 mg nemolizumab or an equivalent thereof.
[0023] In some embodiments, the subject suffers from diffuse scleroderma or limited scleroderma. In some embodiments, the subject suffers from limited scleroderma and has been assigned a score of at least 8 on the modified Rodnan skin score (mRSS). In some embodiments, the subject suffers from diffuse scleroderma and has been assigned a score of at least 12 on the modified Rodnan skin score (mRSS). In some embodiments, the systemic sclerosis has been assigned a score of at least 15 on the modified Rodnan skin score (mRSS).
[0024] In some embodiments, the pharmaceutical composition is formulated for administration by a topical or parenteral route. In some embodiments, the pharmaceutical composition is formulated for subcutaneous administration.
[0025] In some embodiments, the pharmaceutical composition is formulated for administration once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once every eleven weeks.
[0026] In some embodiments, the subject is an adult. In some embodiments, the subject is a pediatric patient.
[0027] In some embodiments, the nemolizumab or equivalent thereof is administered according to a flat dosing regimen with or without a loading dose (i.e., a fixed dose during the treatment period). The loading dose can be about 60 mg to about 120 mg. In some embodiments, the loading dose is between 60mg and 120 mg (e.g., 60, 60.5, 61, 61.5, 62,62.5, 63, 63.5, 64, 64.5, 65, 65.5, 66, 66.5, 67, 67.5, 68, 68.5, 69, 69.5, 70, 70.5, 71, 71.5, 72,72.5, 73, 73.5, 74, 74.5, 75, 75.5, 76, 76.5, 77, 77.5, 78, 78.5, 79, 79.5, 80, 80.5, 81, 81.5, 82,82.5, 83, 83.5, 84, 84.5, 85, 85.5, 86, 86.5, 87, 87.5, 88, 88.5, 89, 89.5, 90, 90.5, 91, 91.5, 92,92.5, 93, 93.5, 94, 94.5, 95, 95.5, 96, 96.5, 97, 97.5, 98, 98.5, 99, 99.5, 100, 100.5, 101,101.5, 102, 102.5, 103, 103.5, 104, 104.5, 105, 105.5, 106, 106.5, 107, 107.5, 108, 108.5, 109, 109.5, 110, 110.5, 111, 111.5, 112, 112.5, 113, 113.5, 114, 114.5, 115, 115.5, 116,-6- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021116.5, 117, 117.5, 118, 118.5, 119, 119.5, or 120 mg). In some embodiments, the loading dose is 60mg. In some embodiments, the loading dose is 120mg. In some embodiments, the nemolizumab or equivalent thereof is administered according to a tiered fixed dosing regimen with or without a loading dose (i.e., using body weight or age cutoffs to define patient strata that receive different flat doses). In some embodiments, the nemolizumab or equivalent thereof is administered according to bodyweight-based dosing (i.e., mg / kg). In some embodiments, the pharmaceutical composition is formulated for administration by a loading dose regimen.
[0028] In some embodiments, the pharmaceutical composition comprises nemolizumab. In some embodiments, the pharmaceutical composition further comprises an anti-inflammatory drug or an immunosuppressive drug. In some embodiments, the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID). In some embodiments, the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.BRIEF DESCRIPTION OF THE FIGURES
[0029] FIG. 1 shows nemolizumab serum concentration during a low dose treatment regimen. Line =median: shaded area=individual values. Simulations based on 1000 resampled datasets generated from the original dataset of 1952 subjects with BW ranging from 31 to 181 kg. BW=body weight; LD=loading dose; PN=prurigo nodularis; Q4W=once every 4 weeks.
[0030] FIG. 2 shows nemolizumab serum concentration during a high dose treatment regimen. Line =median: shaded area=individual values. Simulations based on 1000 resampled datasets generated from the original dataset of 1952 subjects with BW ranging from 31 to 181 kg. BW=body weight; LD=loading dose; PN=prurigo nodularis; Q4W=once every 4 weeks.
[0031] FIG. 3 shows a schematic for a clinical trial to assess treatment of SSc with nemolizumab.-7- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021DETAILED DESCRIPTION
[0032] The present disclosure provides, among other things, methods of treating and treatments for systemic sclerosis. Systemic sclerosis (SSc), also known as scleroderma, is a chronic autoimmune disease characterized by the hardening and thickening of the skin and internal organs. The exact cause of SSc is unknown, but it is believed to be an autoimmune disorder where the body's immune system mistakenly attacks its own tissues. The main symptoms of SSc include: hardening and thickening of the skin, especially on the fingers, hands, face, and arms; Raynaud’s phenomenon (fingers and toes turning white or blue in response to cold or stress); joint pain and stiffness; internal organ involvement, such as heart, lung, kidney, and gastrointestinal problems; and blood vessel abnormalities.
[0033] There are two main types of systemic sclerosis: diffuse scleroderma, which is characterized by widespread skin thickening and early involvement of internal organs, and limited scleroderma, which is limited to the skin and may involve only a few internal organs. The treatments disclosed herein are applicable for treating both diffuse scleroderma and limited scleroderma.
[0034] It is to be appreciated that certain aspects, modes, embodiments, variations and features of the present methods are described below in various levels of detail in order to provide a substantial understanding of the present technology.
[0035] The present disclosure is not to be limited in terms of the particular embodiments described in this application, which are intended as single illustrations of individual aspects of the disclosure. All the various embodiments of the present disclosure will not be described herein. Many modifications and variations of the disclosure can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the disclosure, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the appended claims. The present disclosure is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.-8- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021Definitions
[0036] Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination. Moreover, the disclosure also contemplates that in some embodiments, any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a complex comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination.
[0037] All numerical designations, e.g., pH, temperature, time, concentration, and molecular weight, including ranges, are approximations which are varied (+) or (-) by increments of 1, 5, or 10%. It is to be understood, although not always explicitly stated that all numerical designations are preceded by the term “about.” It also is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art.
[0038] As used herein, the term “approximately” or “about” means plus or minus 10% as well as the specified number. For example, “about 10” should be understood as both “10” and a range encompassing “9-11”.
[0039] As used herein, comparative terms as used herein, such as high, low, increase, decrease, reduce, or any grammatical variation thereof, can refer to certain variation from the reference. In some embodiments, such variation can refer to about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 1 fold, or about 2 folds, or about 3 folds, or about 4 folds, or about 5 folds, or about 6 folds, or about 7 folds, or about 8 folds, or about 9 folds, or about 10 folds, or about 20 folds, or about 30 folds, or about 40 folds, or about 50 folds, or about 60 folds, or about 70 folds, or about 80 folds, or about 90 folds, or about 100 folds or more higher than the reference. In some embodiments, such variation can refer to about 1%, or about 2%, or about 3%, or about 4%, or about 5%, or about 6%, or about 7%, or about 8%, or about 0%, or about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%,-9- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021or about 75%, or about 80%, or about 85%, or about 90%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% of the reference.
[0040] As will be understood by one skilled in the art, for any and all purposes, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Furthermore, as will be understood by one skilled in the art, a range includes each individual member.[00411 “Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.
[0042] As used herein, “and / or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).
[0043] The terms “administer,” “administration,” or “administering” as used herein refer to (1) providing, giving, dosing and / or prescribing, such as by either a health professional or his or her authorized agent or under his direction, and (2) putting into, taking or consuming, such as by a health professional or the subject. Administration shall include without limitation, administration by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intraci sternal injection or infusion, subcutaneous injection, or implant), by inhalation spray nasal, vaginal, rectal, sublingual, urethral (e.g., urethral suppository) or topical routes of administration (e.g., gel, ointment, cream, aerosol, etc.) and can be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, excipients, and vehicles appropriate for each route of administration. The invention is not limited by the route of administration, the formulation or dosing schedule.
[0044] The terms “treat”, “treating” or “treatment”, as used herein, include alleviating, abating, or ameliorating systemic sclerosis (SSc) or one or more symptoms thereof, whether or not SSc is considered to be “cured” or “healed” and whether or not all symptoms are resolved. The terms also include reducing or preventing progression of SSc or one or more-10- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021symptoms thereof, impeding or preventing an underlying mechanism of SSc or one or more symptoms thereof, and achieving any therapeutic benefit.
[0045] As used herein, an “effective amount” is an amount sufficient to effect beneficial or desired results such as alleviating at least one or more symptom of SSc. An effective amount as used herein would also include an amount sufficient to delay the development of SSc, alter the course of an SSc symptom (for example, hardening and tightening of the skin), or reverse a symptom of SSc.
[0046] Interleukin 31 receptor subunit alpha (IL-31 receptor a, IL-3 IRA, IL-3 la, IL-3 la, also known as NR10, glm-r, and GPL) is a protein that forms a heterodimer with oncostatin M receptor (OSMR) and functions as an IL-31 receptor. There are multiple known splicing variants of human-derived IL-3 IRA (WO 00 / 075314): NR10.1 consists of 662 amino acids and contains a transmembrane domain. NR10.2 is a soluble receptor-like protein consisting of 252 amino acids without the transmembrane domain. Meanwhile, known IL-3 IRA splicing variants that function as transmembrane receptor proteins include NR10.3 and IL-31RAV3. IL-3 IRA variants include NR10.3 (also referred to as ILRAv4 (Nat Immunol 5, 752-60, 2004) and IL-31RAv3. NR 10.3 (IL31RAv4) consists of 662 amino acids (WO 00 / 075314; Nat Immunol 5, 752-60, 2004) and IL31RAv3 consists of 732 amino acids (GenBank Accession No: NM — 139017).
[0047] The amino acid sequence of IL31RAv4 is:MKLSPQPSCVNLGMMWTWALWMLPSLCKFSLAALPAKPENISCVYYYRKNLTCTW SPGKETSYTQYTVKRTYAFGEKHDNCTTNSSTSENRASCSFFLPRITIPDNYTIEVEAE NGDGVIKSHMTYWRLENIAKTEPPKIFRVKPVLGIKRMIQIEWIKPELAPVSSDLKYT LRFRTVNSTSWMEVNFAKNRKDKNQTYNLTGLQPFTEYVIALRCAVKESKFWSDWS QEKMGMTEEEAPCGLELWRVLKPAEADGRRPVRLLWKKARGAPVLEKTLGYNIWY YPESNTNLTETMNTTNQQLELHLGGESFWVSMISYNSLGKSPVATLRIPAIQEKSFQCI EVMQACVAEDQLVVKWQSSALDVNTWMIEWFPDVDSEPTTLSWESVSQATNWTIQ QDKLKPFWCYNISVYPMLHDKVGEPYSIQAYAKEGVPSEGPETKVENIGVKTVTITW KEIPKSERKGIICNYTIFYQAEGGKGFSKTVNSSILQYGLESLKRKTSYIVQVMASTSA GGTNGTSINFKTLSFSVFEIILITSLIGGGLLILIILTVAYGLKKPNKLTHLCWPTVPNPA-11- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021ESSIATWHGDDFKDKLNLKESDDSVNTEDRILKPCSTPSDKLVIDKLVVNFGNVLQEI FTDEARTGQENNLGGEKNGTRILSSCPTSI (SEQ ID NO: 1)
[0048] The amino acid sequence of IL31RAv3 is: MMWTWALWMLPSLCKFSLAALPAKPENISCVYYYRKNLTCTWSPGKETSYTQYTVKRTYAFGEKHDNCTTNSSTSENRASCSFFLPRITIPDNYTIEVEAENGDGVIKSHMT YWRLENIAKTEPPKIFRVKPVLGIKRMIQIEWIKPELAPVSSDLKYTLRFRTVNSTSW MEVNFAKNRKDKNQTYNLTGLQPFTEYVIALRCAVKESKFWSDWSQEKMGMTEEE APCGLELWRVLKPAEADGRRPVRLLWKKARGAPVLEKTLGYNIWYYPESNTNLTETMNTTNQQLELHLGGESFWVSMISYNSLGKSPVATLRIPAIQEKSFQCIEVMQACVAE DQLVVKWQSSALDVNTWMIEWFPDVDSEPTTLSWESVSQATNWTIQQDKLKPFWC YNISVYPMLHDKVGEPYSIQAYAKEGVPSEGPETKVENIGVKTVTITWKEIPKSERKG IICNYTIFYQAEGGKGFSKTVNSSILQYGLESLKRKTSYIVQVMASTSAGGTNGTSINF KTLSFSVFEIILITSLIGGGLLILIILTVAYGLKKPNKLTHLCWPTVPNPAESSIATWHGD DFKDKLNLKESDDSVNTEDRILKPCSTPSDKLVIDKLVVNFGNVLQEIFTDEARTGQE NNLGGEKNGYVTCPFRPDCPLGKSFEELPVSPEIPPRKSQYLRSRMPEGTRPEAKEQL LFSGQSLVPDHLCEEGAPNPYLKNSVTAREFLVSEKLPEHTKGEV (SEQ ID NO: 2)
[0049] Mouse-derived IL-3 IRA includes proteins comprising the amino acid sequence: MWTLALWAFSFLCKFSLAVLPTKPENISCVFYFDRNLTCTWRPEKETNDTSYIVTLTYSYGKSNYSDNATEASYSFPRSCAMPPDICSVEVQAQNGDGKVKSDITYWHLISIAK TEPPIILSVNPICNRMFQIQWKPREKTRGFPLVCMLRFRTVNSSRWTEVNFENCKQVC NLTGLQAFTEYVLALRFRFNDSRYWSKWSKEETRVTMEEVPHVLDLWRILEPADMN GDRI< VRLLWI< I< ARGAPVLEI< TFGYHIQYFAENSTNLTEINNITTQQYELLLMSQAHS VSVTSFNSLGKSQEAILRIPDVHEKTFQYIKSMKAYIAEPLLVVNWQSSIPAVDTWIVE WLPEAAMSKFPALSWESVSQVTNWTIEQDKLKPFTCYNISVYPVLGHRVGEPYSIQA YAKEGTPLKGPETRVENIGLRTATITWKEIPKSARNGFINNYTVFYQAEGGKELSKTV NSHALQCDLESLTRRTSYTVWVMASTRAGGTNGVRINFKTLSISVFEIVLLTSLVGGG LLLLSIKTVTFGLRKPNRLTPLCCPDVPNPAESSLATWLGDGFKKSNMKETGNSGDT EDVVLKPCPVPADLIDKLVVNFENFLEVVLTEEAGKGQASILGGEANEYVTSPSRPDGPPGKSFKEPSVLTEVASEDSHSTCSRMADEAYSELARQPSSSCQSPGLSPPREDQAQ NPYLKNSVTTREFLVHENIPEHSKGEV (SEQ ID NO: 3)-12- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0050] Cynomolgus monkey-derived IL-3 IRA includes proteins comprising the amino acid sequence:MMWTWALWMFPLLCKFGLAALPAKPENISCVYYYRKNLTCTWSPGKETSYTQYTA KRTYAFGKKHDNCTTSSSTSENRASCSFFLPRITIPDNYTIEVEAENGDGVIKSDMTC WRLEDIAI< TEPPEIFSVI< PVLGII< RMIRIEWII< PELAPVSSDLI< YALRFRTVNSTSWME VNFAKNRKDTNQTYNLMGLQAFTEYVVALRCAVKESKFWSDWSQEKMGMTEEEA PCGLELWRVLI< PTEVDGRRPVRLLWI< I< ARGAPVLEI< TLGYNIWYFPENNTNLTETV NTTNQQLELHLGGESYWVSMISYNSLGKSPVTTLRIPAIQEKSFRCIEVMQACLAEDQ LVVKWQSSALDVNTWMIEWFPDMDSEHPTLSWESVSQATNWTIQQDKLKPFWCYN ISVYPMLHDKVGEPYSIQAYAKEGIPSKGPETKVENIGVKTVTITWKEIPKSERKGIIC NYTIFYQAEGGKGFSKTVNSSILQYGLESLKRKTSYTVRVMASTSAGGINGTSINFKT LSFSVFEIILITSLIGGGLLILIILTVAYGLKKPNKLTHLCWPSVPNPAESSIATWRGDDF KDKLNLKESDDSVNTEDRILKPCSTPSDKLVIDKSVVNFGNVLQEMFTDEARTGQEN NLGGEKNEYVTHPFRADCPLGKSFEELPVSPEIPPRKSQYLRSRMPEGTCLEAEEQLL VSGQSLESLAPDHVREAAAPNPYLKNSVTTREFLVSQKLPEHTKGEV (SEQ ID NO: 4)
[0051] As used herein, the term “subject” is used interchangeably with “patient,” and indicates a mammal, in particular a human, equine, bovine, porcine, feline, canine, murine, rat, or non-human primate. In some embodiments, the subject is a human. In some embodiments, the subject has been diagnosed with systemic sclerosis for at least 6 months. In some embodiments, the subject suffers from limited scleroderma and has been assigned a score of at least 8 (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51) on the modified Rodnan skin score (mRSS). In some embodiments, the subject suffers from diffuse scleroderma and has been assigned a score of at least 12 (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51) on the mRSS. In some embodiments, the subject has an mRSS of at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 20 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 30 (e.g., 30, 31, 32, 33, 34, 35, 36,-13- 4915-2894-6601.1Atty. Dkt. No.: 105153-1002137, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 40 (e.g., 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51). In some embodiments, the subject has diffuse scleroderma or limited scleroderma.
[0052] As used herein, the term “antibody” collectively refers to immunoglobulins or immunoglobulin-like molecules including by way of example and without limitation, IgA, IgD, IgE, IgG and IgM, combinations thereof or fragments thereof. Fragments of antibodies including, by way of example and without limitation, Fab fragments and single chain variable fragments (scFv), and similar molecules produced during an immune response in any vertebrate, for example, in mammals such as humans, goats, rabbits and mice, as well as nonmammalian species, such as shark immunoglobulins.
[0053] In terms of antibody structure, an immunoglobulin generally has heavy (H) chains and light (L) chains interconnected by disulfide bonds. There are two types of light chain, lambda (X) and kappa (K). There are five main heavy chain classes (or isotypes) which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE. Each heavy and light chain contains a constant region and a variable region, (the regions are also known as "domains"). In combination, the heavy and the light chain variable regions, also called the “Fab region,” specifically bind the antigen. Light and heavy chain variable regions contain a "framework" region interrupted by three hypervariable regions, also called "complementaritydetermining regions" or " CDRs". The extent of the framework region and CDRs has been defined (see, Kabat et al., Sequences of Proteins of Immunological Interest, U. S. Department of Health and Human Services, 1991, which is hereby incorporated by reference). The Kabat database is now maintained online. The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, largely adopts a P-sheet conformation and the CDRs form loops which connect, and in some cases form part of, the P-sheet structure. Thus, framework regions act to form a scaffold that provides for positioning the CDRs in correct orientation by inter-chain, non-covalent interactions.-14- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0054] The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus, and are also typically identified by the chain in which the particular CDR is located. Thus, a VH CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, whereas a VL CDR1 is the CDR1 from the variable domain of the light chain of the antibody in which it is found. An antibody that binds IL-3 IRA will have a specific VH region and the VL region sequence, and thus specific CDR sequences. Antibodies with different specificities (i.e. different combining sites for different antigens) have different CDRs. Although it is the CDRs that vary from antibody to antibody, only a limited number of amino acid positions within the CDRs are directly involved in antigen binding. These positions within the CDRs are called specificity determining residues (SDRs). The base of the antibody plays a role in modulating immune cell activity. This region is called the Fc fragment region (Fc) and is composed of two heavy chains that contribute two or three constant domains depending on the class of the antibody. The Fc region functions to guarantee that each antibody generates an appropriate immune response for a given antigen, by binding to a specific class of proteins found on certain cells, such as B lymphocytes, follicular dendritic cells, natural killer cells, macrophages, neutrophils, etc. and are call “Fc receptors.” Because the constant domains of the heavy chains make up the Fc region of an antibody, the classes of heavy chain in antibodies determine their class effects. The heavy chains in antibodies include alpha, gamma, delta, epsilon, and mu, and correlate to the antibody's isotypes IgA, G, D, E, and M, respectively. This infers different isotypes of antibodies have different class effects due to their different Fc regions binding and activating different types of receptors. There are four subclasses of IgG, which is the most abundant antibody isotype found in human serum. The four subclasses, IgGl, IgG2, IgG3, and IgG4, which are highly conserved.Therapeutic Antibodies of the Disclosed Treatments
[0055] Nemolizumab is a humanized monoclonal antibody that binds to IL-3 IRA.Nemolizumab is annotated as follows: immunoglobulin G2 -kappa, anti-[Homo sapiens IL31RA (interleukin 31 receptor subunit alpha)], humanized monoclonal antibody; gamma2 heavy chain (1-445) [humanized VH (Homo sapiens IGHV1-2*O2 (83.70%) -(IGHD)--15- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021IGHJ5*01) [8.8.14] (1-121) -Homo sapiens IGHG2*01 (CHI C1O> S (135), R12> K (137), E16> G (141), S17> G (142) (122-219), hinge C4> S (223) (220-231), CH2 H30> Q (268) (232-340), CH3 R11> Q (355), Q98> E (419) (341-445)) (122-445)], (224- 214')-disulfide with kappa light chain (1 ’-214’) [humanized V-KAPPA (Homo sapiens IGKV1-39*O1 (82.10%) - IGKJ4*01) [6.3.9] (I'-l 07') -Homo sapiens IGKC*01 (108'- 214')]; dimer (227-227":230-230")-bisdisulfide. Nemolizumab has disulfide bridges at the following locations: Intra-H (C23-C104) 22-96 148-204261-321 367-42522"-96" 148"-204" 261"-321" 367"-425"; Intra-L (C23-C104) 23'-88' 134'-194' 23"'-88'" 134"'-194'"; Inter-H-L (h 5-CL 126) 224-214' 224"-214'"; Inter-H-H (h 8, h 11) 227-227" 230-230". Nemolizumab has N-glycosylation sites at the following locations: H CH2 N84.4: 297, 297". Nemolizumab lacks H chain C-terminal glycine and lysine (CHS Gl>del, K2>del).
[0056] Nemolizumab heavy chain amino acid sequence:QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KSCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYV DGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKT ISKTKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPMLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSP (SEQ ID NO: 5)
[0057] Nemolizumab light chain amino acid sequence:DIQMTQSPSSLSASVGDRVTITCQASEDIYSFVAWYQQKPGKAPKLLIYNAQTEAQGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYDSPLTFGGGTKVEIKRTVAA PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 6)
[0058] The variable domains of the heavy and light chain sequences are shown in bold above, and the CDR sequences are italicized.
[0059] The heavy chain variable region of nemolizumab comprises the amino acid sequence:-16- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0060] QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGL INPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYT LETWGQGTLVTVSS (SEQ ID NO: 7).
[0061] The HCDR1 of nemolizumab comprises the amino acid sequence GYIMN (SEQ ID NO: 8), the HCDR2 comprises the amino acid sequence LINPYNGGTDYNPQFQD (SEQ ID NO: 9), and the HCDR3 comprises the amino acid sequence DGYDDGPYTLET (SEQ ID NO: 10).
[0062] The light chain variable region of nemolizumab comprises the amino acid sequence:
[0063] DIQMTQSPSSLSASVGDRVTITCQASEDIYSFVAWYQQKPGKAPKLLIYNAQT EAQGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYDSPLTFGGGTKVEIKR (SEQ ID NO: 11).
[0064] The LCDR1 of nemolizumab comprises the amino acid sequence QASEDIYSFVA (SEQ ID NO: 12), the LCDR2 comprises the amino acid sequence NAQTEAQ (SEQ ID NO: 13), and the LCDR3 comprises the amino acid sequence QHHYDSPLT (SEQ ID NO: 14).
[0065] Equivalent antibodies to nemolizumab include but are not limited to: (i) antibodies with heavy chains comprising at least 55%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to nemolizumab ’s heavy chain sequence, (ii) antibodies with light chains comprising at least 55%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to nemolizumab ’s light chain sequence, (iii) antibodies with variable regions comprising at least 55%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to nemolizumab ’s variable region sequences, (iv) antibodies with CDRs comprising at least 55%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% amino acid sequence identity to nemolizumab ’s CDR sequences, (v) antibodies that bind to the same isoform of IL-3 IRA as nemolizumab (e.g., IL31-RAv3), optionally the same-17- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021epitope of IL-3 IRA, (vi) antibodies that block or neutralize IL-3 IRA, (vii) antibodies that bind to oncostatin M receptor (OSMR), and (viii) combinations thereof. For example, suitable equivalents include immunoglobulins or immunoglobulin-like molecules with the same or substantially similar heavy and light chain amino acid sequences as nemolizumab. Additional exemplary nemolizumab equivalents are described, for example, in WO 2010 / 064697.
[0066] Equivalents of nemolizumab may be monoclonal or polyclonal antibodies. Such monoclonal antibodies having IL31-RA -binding and / or neutralizing activity can be obtained, for example, by the following procedure: anti-IL31-RA monoclonal antibodies are prepared by using as an antigen IL31-RA or a fragment thereof that is derived from a mammal such as human or mouse by known methods, and then antibodies having IL31-RA-binding and / or neutralizing activity are selected from the thus obtained anti-IL31-RA monoclonal antibodies. Specifically, a desired antigen or cells expressing the desired antigen are used as a sensitizing antigen for immunization according to conventional immunization methods. Anti -IL31-RA monoclonal antibodies can be prepared by fusing the obtained immune cells with known parental cells using conventional cell fusion methods, and screening them for monoclonal antibody-producing cells (hybridomas) by conventional screening methods. Animals to be immunized include, for example, mammals such as mice, rats, rabbits, sheep, monkeys, goats, donkeys, cows, horses, and pigs. The antigen can be prepared using the known IL31-RA gene sequence according to known methods, for example, by methods using baculovirus (for example, WO 98 / 46777).
[0067] The IL31-RA-binding activity of the equivalent antibodies can be determined by methods known to those skilled in the art. Methods for determining the antigen-binding activity of an antibody include, for example, ELISA (enzyme-linked immunosorbent assay), EIA (enzyme immunoassay), RIA (radioimmunoassay), and fluorescent antibody method. For example, when enzyme immunoassay is used, antibody-containing samples, such as purified antibodies and culture supernatants of antibody-producing cells, are added to antigen-coated plates. A secondary antibody labeled with an enzyme, such as alkaline phosphatase, is added and the plates are incubated. After washing, an enzyme substrate, such as p-nitrophenyl phosphate, is added, and the absorbance is measured to evaluate the antigen--18- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021binding activity. The binding and / or neutralizing activity of an equivalent antibody against IL31-RA can be measured, for example, by observing the effect of suppressing the growth of the IL-31 -dependent cell line. For example, the activity of a purified mouse IL-31antibody can be assayed by assessing the IL-31 -dependent growth of Ba / F3 cells transfected with mouse IL-3 IRA and mouse OSMR genes.Systemic Sclerosis
[0068] In some embodiments, systemic sclerosis is scored as none, mild, moderate, or severe. In some embodiments, the scores “none,” “mild,” “moderate,” and “severe” are determined by a modified Rodnan skin score (mRSS) as described by Khanna, Dinesh, et al. (Journal of scleroderma and related disorders 2.1 (2017): 11-18), which is incorporated herein in its entirety. The modified Rodnan skin score (mRSS) is a clinical tool used to assess skin thickness in patients with systemic sclerosis (SSc, scleroderma). It involves a physical examination where the clinician palpates and scores the skin at 17 different body sites, including the fingers, hands, forearms, upper arms, face, chest, abdomen, thighs, legs, and feet. Each site is scored on a scale from 0 to 3, where 0 indicates normal skin, 1 indicates mild thickness, 2 indicates moderate thickness, and 3 indicates severe thickness. The scores from all sites are then summed to give a total score, which can range from 0 to 51. The cutoffs for moderate and severe scleroderma in mRSS are generally defined as follows: Mild Scleroderma: mRSS score of 1-14, Moderate Scleroderma: mRSS score of 15-29, Severe Scleroderma: mRSS score of 30-51. In some embodiments, a subject being treated has diffuse scleroderma. In some embodiments, a subject being treated has limited scleroderma.(0069] SSc is subclassified into diffuse cutaneous SSc (dcSSc or diffuse scelroderma) or limited cutaneous SSc (IcSSc or limited scleroderma) based on the extent of skin involvement. IcSSc is defined as skin thickening distal to the elbows and knees, with or without involvement of the face. dcSSc is characterized by the presence of skin thickening, proximal as well as distal, to the elbows and knees with or without involvement of the face.
[0070] Patients with IcSSc have prominent vascular manifestations, including severe Raynaud phenomenon (RP) and mucocutaneous telangiectasia, and is characterized by slow progression often complicated by pulmonary hypertension (PH). Patients generally develop-19- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021skin sclerosis distal to the elbows and knees, and, to a lesser extent, the face and neck, and may also have gastroesophageal reflux disease. Many patients with IcSSc have manifestations of the CREST syndrome (calcinosis cutis, RP, esophageal dysmotility, sclerodactyly, and telangiectasia).[00711 In addition to having RP, patients with dcSSc are more likely to have internal organs involved, particularly the lung, heart, and kidneys, as well as the gastrointestinal (GI) tract. Patients generally present with puffy hands and develop skin thickening extending proximally to the upper arms, thighs, and / or trunk. This type is typically characterized by a rapid progression of skin thickening with early development of ILD, scleroderma renal crisis (SRC) and cardiac disease.
[0072] Measurement of skin thickness is used as a surrogate for disease activity, severity, and mortality in patients with dcSSc. In early dcSSc, an increase in skin thickening is generally associated with new or worsening internal organ involvement and increased mortality.Worsening mRSS is associated with higher mortality, and both negative renal and cardiac outcomes. Internal organ involvement or worsening are particularly associated with the prior trajectory of skin thickening, and higher skin thickness progression rates are predictive of internal organ involvement and mortality. In addition, patients who never achieved a high skin score have a lower frequency of major organ-based complications, and those with high skin scores that failed to improve by 3 years of disease have significantly higher mortality. Conversely, attenuation of peak skin score or improvement is associated with favorable outcomes, including better survival. These points emphasize the potential benefit of including milder or early cases of SSc in clinical trials, such as designing studies to evaluate either a preventative (less worsening / less peak of mRSS) and / or improvement strategy.
[0073] An effective amount can be administered in one or more administrations, applications or dosages. Such delivery is dependent on a number of variables including the time period for which the individual dosage unit is to be used, the bioavailability of the therapeutic agent, the route of administration, etc. It is understood, however, that specific dose levels of the therapeutic agents of the present disclosure for any particular subject depends upon a variety of factors including the activity of the specific compound employed, the age, body weight,-20- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021general health, sex, and diet of the subject, the time of administration, the rate of excretion, the drug combination, and the severity of the particular disorder being treated and form of administration. Treatment dosages generally may be titrated to optimize safety and efficacy. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. Typically, dosage-effect relationships from in vitro and / or in vivo tests initially can provide useful guidance on the proper doses for patient administration. In general, one will desire to administer an amount of the compound that is effective to achieve a serum level commensurate with the concentrations found to be effective in vitro.
[0074] Dosage regimens for treating SSc may comprise flat dosing (z.e., administering the same dose repeatedly at pre-determined intervals) with or without a loading dose (z.e., administrating an initial dose that is higher or different than subsequent, serial doses). In some embodiments, the loading dose is between 60mg and 120 mg (e.g., 60, 60.5, 61, 61.5, 62, 62.5, 63, 63.5, 64, 64.5, 65, 65.5, 66, 66.5, 67, 67.5, 68, 68.5, 69, 69.5, 70, 70.5, 71, 71.5,72, 72.5, 73, 73.5, 74, 74.5, 75, 75.5, 76, 76.5, 77, 77.5, 78, 78.5, 79, 79.5, 80, 80.5, 81, 81.5,82, 82.5, 83, 83.5, 84, 84.5, 85, 85.5, 86, 86.5, 87, 87.5, 88, 88.5, 89, 89.5, 90, 90.5, 91, 91.5,92, 92.5, 93, 93.5, 94, 94.5, 95, 95.5, 96, 96.5, 97, 97.5, 98, 98.5, 99, 99.5, 100, 100.5, 101,101.5, 102, 102.5, 103, 103.5, 104, 104.5, 105, 105.5, 106, 106.5, 107, 107.5, 108, 108.5, 109, 109.5, 110, 110.5, 111, 111.5, 112, 112.5, 113, 113.5, 114, 114.5, 115, 115.5, 116,116.5, 117, 117.5, 118, 118.5, 119, 119.5, or 120 mg). In some embodiments, the loading dose is 60mg. In some embodiments, the loading dose is 120mg. For the purposes of either type of dosing regimen an effective dose may be administered by enteric (oral, peroral, rectal), by parenteral (intravascular, intramuscular, subcutaneous, and inhalation administration) or by topical (skin and mucosal membranes) routes. In some embodiments, nemolizumab or the equivalent thereof is administered subcutaneously.
[0075] In some embodiments, a loading dose and the subsequent serial doses may be administered via the same route (e.g., subcutaneously), while in some embodiments, a loading dose and the subsequent serial doses may be administered via different routes (e.g., parenterally and subcutaneously, respectively).-21- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021Treatment for Systemic Sclerosis
[0076] The present disclosure provides treatments for systemic sclerosis (SSc), which comprise, consist of, or consist essentially of administering an effective amount of nemolizumab or an equivalent thereof to the subject.
[0077] In one aspect, the disclosure is directed to a method for treating systemic sclerosis, comprising administering to a subject with systemic sclerosis (a) at least 30 mg and up to 110 mg or at least 30 mg and up to 90 mg (e.g., 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 9070, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109 mg or any value therebetween) of nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 140 mg or at least 60 mg and up to 120 mg (60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111,112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129,130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140 mg or any value therebetween) of nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg.
[0078] The administration methods can be properly selected according to the patient's age, patient's body weight and condition. Applicant found that, in some embodiments, treatment of systemic sclerosis, which involves fibrous tissue formation, utilizes administration of higher doses than the treatment of other inflammatory diseases such as prurigo nodularis (PN) or atopic dermatitis (AD). In some embodiments, treatment of systemic sclerosis utilizes administration of about the same dose as the treatment of other inflammatory diseases such as PN or atopic dermatitis AD.
[0079] In some embodiments, administration dose is selected, for example, from within the range of 0.5 to 100 mg of the active ingredient per kg body weight (e.g., 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5,-22- 4915-2894-6601.1Atty. Dkt. No.: 105153-1002125, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 30.5, 31, 31.5, 32, 32.5, 33, 33.5, 34, 34.5,35, 35.5, 36, 36.5, 37, 37.5, 38, 38.5, 39, 39.5, 40, 40.5, 41, 41.5, 42, 42.5, 43, 43.5, 44, 44.5,45, 45.5, 46, 46.5, 47, 47.5, 48, 48.5, 49, 49.5, 50, 50.5, 51, 51.5, 52, 52.5, 53, 53.5, 54, 54.5,55, 55.5, 56, 56.5, 57, 57.5, 58, 58.5, 59, 59.5, 60, 60.5, 61, 61.5, 62, 62.5, 63, 63.5, 64, 64.5,65, 65.5, 66, 66.5, 67, 67.5, 68, 68.5, 69, 69.5, 70, 70.5, 71, 71.5, 72, 72.5, 73, 73.5, 74, 74.5,75, 75.5, 76, 76.5, 77, 77.5, 78, 78.5, 79, 79.5, 80, 80.5, 81, 81.5, 82, 82.5, 83, 83.5, 84, 84.5,85, 85.5, 86, 86.5, 87, 87.5, 88, 88.5, 89, 89.5, 90, 90.5, 91, 91.5, 92, 92.5, 93, 93.5, 94, 94.5,95, 95.5, 96, 96.5, 97, 97.5, 98, 98.5, 99, 99.5, 100 mg / kg).
[0080] In some embodiments, the dose of the active ingredient is selected from within the range of 0.5 to 10 mg / kg body weight. In some embodiments, the composition is formulated to administer a dose containing, for example, about 0.5 to 50 mg / kg, about 0.5 mg / kg to about 0.1 mg / kg, about 0.75 mg / kg to 2 mg / kg, about 0.4 mg / kg to about 0.8 mg / kg, about 0.4 mg / kg to about 1.8 mg / kg, about 0.5 to about 2.5 mg / kg, about 0.8 mg / kg to about 2.2 mg / kg, about 1 mg / kg to about 2.5 mg / kg, about 1 mg / kg to about 3.5 mg / kg, about 1 mg / kg to about 5 mg / kg, about 2 mg / kg to about 4 mg / kg, about 2.5 mg / kg to about 10 mg / kg, about 5 mg / kg to about 10 mg / kg, about 10 mg / kg to about 20 mg / kg, about 10 mg / kg to about 40 mg / kg, about 20 mg / kg to about 50 mg / kg, about 25 mg / kg to about 75 mg / kg, about 50 mg / kg to about 100 mg / kg, or about 100 mg / kg to about 500 mg / kg, or about 100 mg / kg to about 1000 mg / kg body weight of nemolizumab or an equivalent thereof. In some embodiments, the dose ranges from about 0.01 mg / kg to about 0.1 mg / kg, about 0.1 mg / kg to about 0.5 mg / kg, about 0.5 mg / kg to about 1.5 mg / kg, about 1.5 mg / kg to about 2.5 mg / kg, or about 2.5 mg / kg to about 10 mg / kg. In some embodiments, the dose is about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, about 0.9 mg / kg, about 1 mg / kg, about 1.1 mg / kg, about 1.2 mg / kg, about 1.3 mg / kg, about 1.4 mg / kg, about 1.5 mg / kg, about 1.6 mg / kg, about 1.7 mg / kg, about 1.8 mg / kg, about 1.9 mg / kg, about 2 mg / kg, about 2.1 mg / kg, about 2.2 mg / kg, about 2.3 mg / kg, about 2.4 mg / kg, about 2.5 mg / kg, about 2.6 mg / kg, about 2.7 mg / kg, about 2.8 mg / kg, about 2.9 mg / kg, about 3 mg / kg, about 3.5 mg / kg, about 4 mg / kg, about 4.5 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, or any value therebetween. In some embodiments, the effective amount of nemolizumab or the equivalent thereof is about 1 mg / kg, about 1.5 mg / kg, about 2-23- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021mg / kg, about 2.5 mg / kg, or 3 mg / kg. In some embodiments, the dose is about 0.5 mg / kg. In some embodiments, the dose is about 2 mg / kg.
[0081] In some embodiments, the subject has systemic sclerosis (SSc). In some embodiments, the subject suffers from one or more, moderate to severe systemic sclerosis. In some embodiments, the subject has been diagnosed of SSc for at least about 6 months. In some embodiments, the systemic sclerosis is a diffuse scleroderma or a limited scleroderma. In some embodiments, the subject suffers from limited scleroderma and has been assigned a score of at least 8 (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51) on the modified Rodnan skin score (mRSS). In some embodiments, the subject suffers from diffuse scleroderma and has been assigned a score of at least 12 (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)on the modified Rodnan skin score (mRSS). In some embodiments, the subject has a modified Rodnan skin score (mRSS) of at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 20 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 30 (e.g., 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 40 (e.g., 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50 or 51).
[0082] In some embodiments, the disclosed compositions and methods result in reduced SSc symptoms in a patient, e.g., reduced digital vasculopathy, reduced involvement of the skin, musculoskeletal, GI, pulmonary, cardiac, renal, neuromuscular, and genitourinary systems (e.g., reduced skin fibrosis, and SSc-associated interstitial lung disease (SSc ILD)).
[0083] SSc-associated interstitial lung disease (SSc ILD) is a chronic condition where scar tissue (fibrosis) and / or inflammation accumulate in the interstitium of the lungs of individuals diagnosed with SSc. This lung disease can be progressive, debilitating, potentially life threatening and is the leading cause of death in people with SSc. Skin fibrosis is a hallmark-24- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021feature of SSc. It results from excessive deposition of collagen and other extracellular matrix components in the skin. In severe cases, the skin becomes thickened, taut, and less elastic. Patients often experience difficulty moving their joints due to the restricted skin mobility.
[0084] In some embodiments, the subject does not have atopic dermatitis. In some embodiments of the uses, the subject does not have chronic pruritus resulting from a condition other than prurigo nodularis (PN), such as scabies, insect bite, lichen simplex chronicus, psoriasis, acne, folliculitis, habitual picking, lymphomatoid papulosis, chronic actinic dermatitis, dermatitis herpetiformis, sporotrichosis, bullous disease. In some embodiments of the uses, the subject does not have neuropathic or psychogenic pruritus, such as notalgia paresthetica, brachioradial pruritus, dilutional parasitosis, pathomimia.
[0085] In some embodiments, the nemolizumab or the equivalent thereof is administered by a by enteric (oral, peroral, rectal), by parenteral (intravascular, intramuscular, subcutaneous, and inhalation administration) or by topical (skin and mucosal membranes) routes. In some embodiments, the nemolizumab or the equivalent thereof is administered subcutaneously.
[0086] In some embodiments, the nemolizumab or the equivalent thereof is administered daily, every other day, twice per week, three times per week, four times per week, five times per week, six times per week, once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every 10 weeks, once every 11 weeks, once every 12 weeks, every 13 weeks, every 14 weeks, twice per year, once per year, and / or as needed based on the appearance of symptoms of systemic sclerosis. In a specific embodiment, the nemolizumab or the equivalent thereof is administered once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks,, once every nine weeks, once every ten weeks, or once every eleven weeks. In a specific embodiment, the nemolizumab or the equivalent thereof is administered every four weeks or every eight weeks.
[0087] In some embodiments, the duration of treatment is about one day, about one week, about two weeks, about three weeks, about four weeks, about five weeks, about six weeks,-25- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021about seven weeks, about eight weeks, about nine weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 24 weeks, about 30 weeks, about 36 weeks, about 40 weeks, about 48 weeks, about 50 weeks, about one year, about two years, about three years, about four years, about five years, or as needed based on the appearance of symptoms of systemic sclerosis (SSc). In some embodiments, duration of treatment is about 12 weeks to about 24 weeks, about 12 to about 36 weeks, about 12 to about 48 weeks, or about 24 to about 36 weeks.
[0088] In some embodiments, the subject is an adult. In some embodiments, the subject is a pediatric patient. As used herein, the term “adult” refers to a subject who is 18 years old or older. As used herein, the term “pediatric” refers to a subject who is younger than 18 years old.
[0089] In some embodiments, the nemolizumab or equivalent thereof is administered according to a flat dosing regimen with or without a loading dose (i.e., a fixed dose during the treatment period). In some embodiments, the loading dose is between 60mg and 120 mg (e.g., 60, 60.5, 61, 61.5, 62, 62.5, 63, 63.5, 64, 64.5, 65, 65.5, 66, 66.5, 67, 67.5, 68, 68.5, 69,69.5, 70, 70.5, 71, 71.5, 72, 72.5, 73, 73.5, 74, 74.5, 75, 75.5, 76, 76.5, 77, 77.5, 78, 78.5, 79,79.5, 80, 80.5, 81, 81.5, 82, 82.5, 83, 83.5, 84, 84.5, 85, 85.5, 86, 86.5, 87, 87.5, 88, 88.5, 89,89.5, 90, 90.5, 91, 91.5, 92, 92.5, 93, 93.5, 94, 94.5, 95, 95.5, 96, 96.5, 97, 97.5, 98, 98.5, 99,99.5, 100, 100.5, 101, 101.5, 102, 102.5, 103, 103.5, 104, 104.5, 105, 105.5, 106, 106.5, 107,107.5, 108, 108.5, 109, 109.5, 110, 110.5, 111, 111.5, 112, 112.5, 113, 113.5, 114, 114.5,115, 115.5, 116, 116.5, 117, 117.5, 118, 118.5, 119, 119.5, or 120 mg). In some embodiments, the loading dose is 60mg. In some embodiments, the loading dose is 120mg. In some embodiments, the nemolizumab or equivalent thereof is administered according to a tiered fixed dosing regimen with or without a loading dose (i.e., using body weight or age cutoffs to define patient strata that receive different flat doses). In some embodiments, the loading dose is between 60mg and 120 mg (e.g., 60, 60.5, 61, 61.5, 62, 62.5, 63, 63.5, 64,64.5, 65, 65.5, 66, 66.5, 67, 67.5, 68, 68.5, 69, 69.5, 70, 70.5, 71, 71.5, 72, 72.5, 73, 73.5, 74,74.5, 75, 75.5, 76, 76.5, 77, 77.5, 78, 78.5, 79, 79.5, 80, 80.5, 81, 81.5, 82, 82.5, 83, 83.5, 84,84.5, 85, 85.5, 86, 86.5, 87, 87.5, 88, 88.5, 89, 89.5, 90, 90.5, 91, 91.5, 92, 92.5, 93, 93.5, 94,-26- 4915-2894-6601.1Atty. Dkt. No.: 105153-1002194.5, 95, 95.5, 96, 96.5, 97, 97.5, 98, 98.5, 99, 99.5, 100, 100.5, 101, 101.5, 102, 102.5, 103,103.5, 104, 104.5, 105, 105.5, 106, 106.5, 107, 107.5, 108, 108.5, 109, 109.5, 110, 110.5, 111, 111.5, 112, 112.5, 113, 113.5, 114, 114.5, 115, 115.5, 116, 116.5, 117, 117.5, 118,118.5, 119, 119.5, or 120 mg). In some embodiments, the loading dose is 60mg. In some embodiments, the loading dose is 120mg. In some embodiments, the nemolizumab or equivalent thereof is administered according to bodyweight-based dosing (i.e., mg / kg). In some embodiments, the pharmaceutical composition is formulated for administration by a loading dose regimen.
[0090] In some embodiments, the subject is administered nemolizumab. In some embodiments, the subject is further administered an effective amount of an anti-inflammatory drug or an immunosuppressive drug. In some embodiments, the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID). In some embodiments, the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.
[0091] In another aspect, the disclosure is directed to a use of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of systemic sclerosis, wherein the medicament comprises a dosage of nemolizumab or an equivalent thereof that is (a) at least 30 mg and up to 90 mg or higher (e.g., 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42,43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110 mg or any value therebetween) nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 120 mg or higher (60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140 mg or any value therebetween) nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg.-27- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0092] Another aspect of the disclosure is directed to a use of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of systemic sclerosis, wherein the medicament comprises a dosage of nemolizumab or an equivalent thereof that is at least 30 mg and up to 120 mg or higher (30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69,70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114,115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140 mg or any value therebetween) nemolizumab or an equivalent thereof.
[0093] In some embodiments, the subject has systemic sclerosis (SSc). In some embodiments, the subject suffers from one or more, moderate to severe systemic sclerosis. In some embodiments, the subject has been diagnosed of SSc for at least about 6 months. In some embodiments, the subject suffers from limited scleroderma and has been assigned a score of at least 8 (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51) on the modified Rodnan skin score (mRSS). In some embodiments, the subject suffers from diffuse scleroderma and has been assigned a score of at least 12 (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)on the modified Rodnan skin score (mRSS). In some embodiments, the subject has a modified Rodnan skin score (mRSS) of at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 20 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 30 (e.g., 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 40 (e.g., 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50 or 51).-28- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0094] In some embodiments, the medicament is formulated for administration by a topical or parenteral route. In some embodiments, the medicament is formulated for subcutaneous administration.
[0095] In some embodiments, the medicament is formulated for administration daily, every other day, twice per week, three times per week, four times per week, five times per week, six times per week, once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every 10 weeks, once every 11 weeks, once every 12 weeks, every 13 weeks, every 14 weeks, twice per year, once per year, and / or as needed based on the appearance of symptoms of systemic sclerosis. In a specific embodiment, the medicament is formulated for administration once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once every eleven weeks. In a specific embodiment, the medicament is formulated for administration every four weeks or every eight weeks.
[0096] In some embodiments, the subject is an adult. In some embodiments, the subject is a pediatric patient.
[0097] In some embodiments, the medicament is formulated for administration by a flat dosing regimen. In some embodiments, the medicament is formulated for administration by a loading dose regimen.
[0098] In some embodiments, the medicament comprises nemolizumab. In some embodiments, the medicament further comprises an anti-inflammatory drug or an immunosuppressive drug. In some embodiments, the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID). In some embodiments, the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.-29- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021Pharmaceutical Compositions
[0099] Pharmaceutical compositions comprising nemolizumab or an equivalent thereof are provided herein for use in treating systemic sclerosis.
[0100] In one aspect, provided are pharmaceutical compositions for use in the treatment of a subject having systemic sclerosis (SSc), the composition comprising, consisting of, or consisting essentially of nemolizumab or an equivalent thereof. Moreover, the present disclosure provides therapeutic agents for SSc which comprise nemolizumab or an equivalent thereof as an active ingredient.
[0101] In some embodiments, the pharmaceutical composition comprises nemolizumab or an equivalent thereof for treatment of systemic sclerosis, wherein the pharmaceutical composition comprises a dosage of nemolizumab or an equivalent thereof that is (a) at least 30 mg and up to 90 mg (e.g., 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71,72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 mg or any value therebetween) nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 120 mg (60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72,73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116,117, 118, 119, 120 mg or any value therebetween) nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg.
[0102] In some embodiments, the pharmaceutical composition comprising nemolizumab or an equivalent thereof for treatment of systemic sclerosis, wherein the pharmaceutical composition comprises a dosage of nemolizumab or an equivalent thereof that is at least 30 mg and up to 120 mg (30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98,99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117,118, 119, 120 mg or any value therebetween) nemolizumab or an equivalent thereof.-30- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0103] In some embodiments, the subject has systemic sclerosis (SSc). In some embodiments, the subject suffers from one or more, moderate to severe systemic sclerosis. In some embodiments, the subject has been diagnosed of SSc for at least about 6 months. In some embodiments, the systemic sclerosis is a diffuse scleroderma or a limited scleroderma. In some embodiments, the subject suffers from limited scleroderma and has been assigned a score of at least 8 (e.g., 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51) on the modified Rodnan skin score (mRSS). In some embodiments, the subject suffers from diffuse scleroderma and has been assigned a score of at least 12 (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)on the modified Rodnan skin score (mRSS). In some embodiments, the subject has a modified Rodnan skin score (mRSS) of at least 15 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 20 (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 30 (e.g., 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,48, 49, 50 or 51). In some embodiments, the subject has an mRSS of at least 40 (e.g., 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50 or 51).
[0104] The phrase “comprise(s) nemolizumab or an equivalent thereof as an active ingredient” means comprising nemolizumab or an equivalent thereof as at least one of the active ingredients, and does not limit the proportion of the antibody. In addition, the therapeutic agents for systemic sclerosis in the present disclosure may also comprise, in combination with nemolizumab or an equivalent thereof, other ingredients that enhance the treatment of systemic sclerosis. For example, the composition may comprise one or more topical corticosteroid creams or injections, ointments with menthol or phenol to cool and soothe itchy skin, capsaicin cream, oral corticosteroids, selective serotonin reuptake inhibitors (SSRIs), and oral antihistamines.
[0105] Pharmaceutical compositions of nemolizumab or an equivalent thereof of the present disclosure can be prepared as formulations according to standard methods (see, for example,-31- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021Remington's Pharmaceutical Science, Mark Publishing Company, Easton, USA). In some embodiments, the pharmaceutical compositions comprise a carrier and / or additive. In some embodiments, the carrier is a pharmaceutically acceptable carrier. For example, in some embodiments, the pharmaceutical composition comprises one or more surfactants (for example, PEG and Tween), excipients, antioxidants (for example, ascorbic acid), coloring agents, flavoring agents, preservatives, stabilizers, buffering agents (for example, phosphoric acid, citric acid, and other organic acids), chelating agents (for example, EDTA), suspending agents, isotonizing agents, binders, disintegrators, lubricants, fluidity promoters, corrigents, light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmelose calcium, carmelose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylacetaldiethylaminoacetate, polyvinylpyrrolidone, gelatin, medium chain fatty acid triglyceride, polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethylcellulose, corn starch, and inorganic salt. In some embodiments, the pharmaceutical composition comprises one or more other low-molecular-weight polypeptides, proteins such as serum albumin, gelatin, and immunoglobulin, and amino acids such as glycine, glutamine, asparagine, arginine, and lysine.
[0106] When nemolizumab or an equivalent thereof is prepared as an aqueous solution for injection, nemolizumab or an equivalent thereof may be dissolved in an isotonic solution containing, for example, physiological saline, dextrose, or other adjuvants. The adjuvants may include, for example, D-sorbitol, D-mannose, D-mannitol, and sodium chloride. In addition, appropriate solubilizing agents, for example, alcohols (for example, ethanol), polyalcohols (for example, propylene glycols and PEGs), and non-ionic detergents (polysorbate 80 and HCO-50) may be used concomitantly.
[0107] If necessary, nemolizumab or an equivalent thereof may be encapsulated in microcapsules (microcapsules made of hydroxymethylcellulose, gelatin, polymethylmethacrylate, and the like), and made into components of colloidal drug delivery systems (liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) (for example, see “Remington's Pharmaceutical Science 16th edition” &, Oslo Ed. (1980)). Moreover, methods for making sustained-release drugs are known, and these can be applied for nemolizumab or an equivalent thereof (Langer et al., J. Biomed. Mater. Res.-32- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021(1981) 15, 167-277; Langer, Chem. Tech. (1982) 12, 98-105; U. S. Pat. No. 3,773,919;European Patent Application (EP) No. 58,481; Sidman et al., Biopolymers (1983) 22, 547-56; EP 133,988).
[0108] The pharmaceutical compositions of the present disclosure can be administered either orally or parenterally. Specifically, the pharmaceutical compositions are administered to patients by injection or percutaneous administration. Injections include, for example, intravenous injections, intramuscular injections, and subcutaneous injections, for systemic or local administration. The pharmaceutical compositions may be given to sites where inflammation is to be suppressed, or areas surrounding the sites by local infusion or intramuscular injection.
[0109] The administration methods can be properly selected according to the patient's age patient's body weight and condition. The single-administration dose can be selected, for example, from within the range of 0.5 to 100 mg of the active ingredient per kg body weight (e.g., 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12,12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22,22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 30.5, 31, 31.5, 32,32.5, 33, 33.5, 34, 34.5, 35, 35.5, 36, 36.5, 37, 37.5, 38, 38.5, 39, 39.5, 40, 40.5, 41, 41.5, 42,42.5, 43, 43.5, 44, 44.5, 45, 45.5, 46, 46.5, 47, 47.5, 48, 48.5, 49, 49.5, 50, 50.5, 51, 51.5, 52,52.5, 53, 53.5, 54, 54.5, 55, 55.5, 56, 56.5, 57, 57.5, 58, 58.5, 59, 59.5, 60, 60.5, 61, 61.5, 62,62.5, 63, 63.5, 64, 64.5, 65, 65.5, 66, 66.5, 67, 67.5, 68, 68.5, 69, 69.5, 70, 70.5, 71, 71.5, 72,72.5, 73, 73.5, 74, 74.5, 75, 75.5, 76, 76.5, 77, 77.5, 78, 78.5, 79, 79.5, 80, 80.5, 81, 81.5, 82,82.5, 83, 83.5, 84, 84.5, 85, 85.5, 86, 86.5, 87, 87.5, 88, 88.5, 89, 89.5, 90, 90.5, 91, 91.5, 92,92.5, 93, 93.5, 94, 94.5, 95, 95.5, 96, 96.5, 97, 97.5, 98, 98.5, 99, 99.5, 100 mg / kg). In some embodiments, the single-administration dose is selected from within the range of 0.05 mg to 10 mg of the active ingredient per kg body weight (e.g., 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.05, 1.1, 1.15, 1.2, 1.25, 1.3,1.35, 1.4, 1.45, 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95, 2, 2.05, 2.1, 2.15, 2.2, 2.25,2.3, 2.35, 2.4, 2.45, 2.5, 2.55, 2.6, 2.65, 2.7, 2.75, 2.8, 2.85, 2.9, 2.95, 3, 3.05, 3.1, 3.15, 3.2,3.25, 3.3, 3.35, 3.4, 3.45, 3.5, 3.55, 3.6, 3.65, 3.7, 3.75, 3.8, 3.85, 3.9, 3.95, 4, 4.05, 4.1, 4.15,4.2, 4.25, 4.3, 4.35, 4.4, 4.45, 4.5, 4.55, 4.6, 4.65, 4.7, 4.75, 4.8, 4.85, 4.9, 4.95, 5, 5.05, 5.1,-33- 4915-2894-6601.1Atty. Dkt. No.: 105153-100215.15, 5.2, 5.25, 5.3, 5.35, 5.4, 5.45, 5.5, 5.55, 5.6, 5.65, 5.7, 5.75, 5.8, 5.85, 5.9, 5.95, 6, 6.05, 6.1, 6.15, 6.2, 6.25, 6.3, 6.35, 6.4, 6.45, 6.5, 6.55, 6.6, 6.65, 6.7, 6.75, 6.8, 6.85, 6.9, 6.95, 7, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, 7.4, 7.45, 7.5, 7.55, 7.6, 7.65, 7.7, 7.75, 7.8, 7.85, 7.9, 7.95, 8, 8.05, 8.1, 8.15, 8.2, 8.25, 8.3, 8.35, 8.4, 8.45, 8.5, 8.55, 8.6, 8.65, 8.7, 8.75, 8.8, 8.85, 8.9, 8.95, 9, 9.05, 9.1, 9.15, 9.2, 9.25, 9.3, 9.35, 9.4, 9.45, 9.5, 9.55, 9.6, 9.65, 9.7, 9.75, 9.8, 9.85, 9.9, 9.95, 10 mg / kg, or any value therebetween). Alternatively, for example, when the agents are administered to human patients, the dose of the active ingredient can be selected from within the range of 0.5 to 10 mg / kg body weight. In some embodiments, the composition is formulated to administer a dose containing, for example, about 0.5 to 50 mg / kg, about 0.5 mg / kg to about 0.1 mg / kg, about 0.75 mg / kg to 2 mg / kg, about 0.4 mg / kg to about 0.8 mg / kg, about 0.4 mg / kg to about 1.8 mg / kg, about 0.5 to about 2.5 mg / kg, about 0.8 mg / kg to about 2.2 mg / kg, about 1 mg / kg to about 2.5 mg / kg, about 1 mg / kg to about 3.5 mg / kg, about 1 mg / kg to about 5 mg / kg, about 2 mg / kg to about 4 mg / kg, about 2.5 mg / kg to about 10 mg / kg, about 5 mg / kg to about 10 mg / kg body weight of nemolizumab or an equivalent thereof. In some embodiments, the dose ranges from about 0.01 mg / kg to about 0.1 mg / kg, about 0.1 mg / kg to about 0.5 mg / kg, about 0.5 mg / kg to about 1.5 mg / kg, about 1.5 mg / kg to about 2.5 mg / kg, or about 2.5 mg / kg to about 10 mg / kg. In some embodiments, the dose is about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, about 0.9 mg / kg, about 1 mg / kg, about 1.1 mg / kg, about 1.2 mg / kg, about 1.3 mg / kg, about 1.4 mg / kg, about 1.5 mg / kg, about 1.6 mg / kg, about 1.7 mg / kg, about 1.8 mg / kg, about 1.9 mg / kg, about 2 mg / kg, about 2.1 mg / kg, about 2.2 mg / kg, about 2.3 mg / kg, about 2.4 mg / kg, about 2.5 mg / kg, about 2.6 mg / kg, about 2.7 mg / kg, about 2.8 mg / kg, about 2.9 mg / kg, about 3 mg / kg, about 3.5 mg / kg, about 4 mg / kg, about 4.5 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, or about 10 mg / kg. In some embodiments, the effective amount of nemolizumab or the equivalent thereof is about 1 mg / kg, about 1.5 mg / kg, about 2 mg / kg, about 2.5 mg / kg, or about 3 mg / kg. In some embodiments, the dose is about 0.5 mg / kg. In some embodiments, the dose is about 2 mg / kg.
[0110] In some embodiments, the pharmaceutical composition is formulated for administration daily, every other day, twice per week, three times per week, four times per week, five times per week, six times per week, once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once-34- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021every seven weeks, once every eight weeks, once every nine weeks, once every 10 weeks, once every 11 weeks, once every 12 weeks, every 13 weeks, every 14 weeks, twice per year, once per year, and / or as needed based on the appearance of symptoms of systemic sclerosis. In a specific embodiment, the pharmaceutical composition is formulated for administration once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once every eleven weeks. In a specific embodiment, the pharmaceutical composition is formulated for administration every four weeks or every eight weeks.
[0111] In some embodiments, the pharmaceutical composition comprises nemolizumab. In some embodiments, the pharmaceutical composition further comprises an anti-inflammatory drug or an immunosuppressive drug. In some embodiments, the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID). In some embodiments, the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.Select Embodiments
[0112] Embodiment 1: A method for treating systemic sclerosis, comprising administering to a subject with systemic sclerosis (a) at least 30 mg and up to 90 mg of nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 120 mg of nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg.
[0113] Embodiment 2: A method for treating systemic sclerosis, comprising administering to a subject with systemic sclerosis at least 30 mg and up to 120 mg of nemolizumab or an equivalent thereof.
[0114] Embodiment 3: The method of embodiment 1 or 2, wherein the subject suffers from one or more, moderate to severe systemic sclerosis.-35- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0115] Embodiment 4: The method of any one of embodiments 1-3, wherein the systemic sclerosis is a diffuse scleroderma or a limited scleroderma.
[0116] Embodiment 5: The method of any one of embodiments 1-4, wherein the systemic sclerosis has been assigned a score of at least 15 on the modified Rodnan skin score (mRSS).
[0117] Embodiment 6: The method of any one of embodiments 1-5, wherein the nemolizumab or the equivalent thereof is administered by an enteric, a topical or a parenteral route.
[0118] Embodiment 7: The method of any one of embodiments 1-5, wherein the nemolizumab or the equivalent thereof is administered subcutaneously.
[0119] Embodiment 8: The method of any one of embodiments 1-7, wherein the nemolizumab or the equivalent thereof is administered once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once every eleven weeks.
[0120] Embodiment 9: The method of any one of embodiments 1-8, wherein the subject is an adult.
[0121] Embodiment 10: The method of any one of embodiments 1-8, wherein the subject is a pediatric patient.
[0122] Embodiment 11: The method of any one of embodiments 1-10, wherein the nemolizumab or equivalent thereof is administered according to a flat dosing regimen.
[0123] Embodiment 12: The method of any one of embodiments 1-11, wherein the nemolizumab or equivalent thereof is administered according to a loading dose regimen.
[0124] Embodiment 13: The method of any one of embodiments 1-12, wherein the subject is administered nemolizumab.-36- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0125] Embodiment 14: The method of any one of embodiments 1-13, further comprising administering an effective amount of an anti-inflammatory drug or an immunosuppressive drug.
[0126] Embodiment 15: The method of embodiment 14, wherein the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID).
[0127] Embodiment 16: The method of embodiment 14, wherein the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.
[0128] Embodiment 17: Use of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of systemic sclerosis in a subject in need, wherein the medicament comprises a dosage of nemolizumab or an equivalent thereof that is (a) at least 30 mg and up to 90 mg nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 120 mg nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg.
[0129] Embodiment 18: Use of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of systemic sclerosis, wherein the medicament comprises a dosage of nemolizumab or an equivalent thereof that is at least 30 mg and up to 120 mg nemolizumab or an equivalent thereof.
[0130] Embodiment 19: The use of embodiment 17 or embodiment 18, wherein the subject suffers from one or more, moderate to severe systemic sclerosis.
[0131] Embodiment 20: The use of any one of embodiments 17-19, wherein the systemic sclerosis is a diffuse scleroderma or a limited scleroderma.
[0132] Embodiment 21: The use of any one of embodiments 17-21, wherein the systemic sclerosis has been assigned a score of at least 15 on the modified Rodnan skin score (mRSS).
[0133] Embodiment 22: The use of any one of embodiments 17-21, wherein the medicament is formulated for administration by an enteric, a topical or a parenteral route.-37- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0134] Embodiment 23: The use of any one of embodiments 17-21, wherein the medicament is formulated for subcutaneous administration.
[0135] Embodiment 24: The use of any one of embodiments 17-23, wherein the medicament is formulated for administration once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once every eleven weeks.
[0136] Embodiment 25: The use of any one of embodiments 17-24, wherein the subject is an adult.
[0137] Embodiment 26: The use of any one of embodiments 17-24, wherein the subject is a pediatric patient.
[0138] Embodiment 27: The use of any one of embodiments 17-26, wherein the medicament is formulated for administration by a flat dosing regimen.
[0139] Embodiment 28: The use of any one of embodiments 17-26, wherein the medicament is formulated for administration by a loading dose regimen.
[0140] Embodiment 29: The use of any one of embodiments 17-28, wherein the medicament comprises nemolizumab.
[0141] Embodiment 30: The use of any one of embodiments 17-29, wherein the medicament further comprises an anti-inflammatory drug or an immunosuppressive drug.
[0142] Embodiment 31: The use of embodiment 30, wherein the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID).
[0143] Embodiment 32: The use of embodiment 30, wherein the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.-38- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0144] Embodiment 33: A pharmaceutical composition comprising nemolizumab or an equivalent thereof for treatment of systemic sclerosis in a subject in need, wherein the pharmaceutical composition comprises a dosage of nemolizumab or an equivalent thereof that is (a) at least 30 mg and up to 90 mg nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 120 mg nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg.
[0145] Embodiment 34: A pharmaceutical composition comprising nemolizumab or an equivalent thereof for treatment of systemic sclerosis, wherein the pharmaceutical composition comprises a dosage of nemolizumab or an equivalent thereof that is at least 70 mg and up to 140 mg nemolizumab or an equivalent thereof.
[0146] Embodiment 35: The pharmaceutical composition of embodiment 33 or 34, wherein the subject suffers from one or more, moderate to severe systemic sclerosis.
[0147] Embodiment 36: The pharmaceutical composition of any one of embodiments 33-35, wherein the systemic sclerosis is a diffuse scleroderma or a limited scleroderma.
[0148] Embodiment 37: The pharmaceutical composition of any one of embodiments 33-36, wherein the systemic sclerosis has been assigned a score of at least 15 on the modified Rodnan skin score (mRSS).
[0149] Embodiment 38: The pharmaceutical composition of any one of embodiments 33-37, wherein the pharmaceutical composition is formulated for administration by a topical or parenteral route.
[0150] Embodiment 39: The pharmaceutical composition of any one of embodiments 33-37, wherein the pharmaceutical composition is formulated for subcutaneous administration.
[0151] Embodiment 40: The pharmaceutical composition of any one of embodiments 33-39, wherein the pharmaceutical composition is formulated for administration once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once every eleven weeks.-39- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0152] Embodiment 41: The pharmaceutical composition of any one of embodiments 33-40, wherein the subject is an adult.
[0153] Embodiment 42: The pharmaceutical composition of any one of embodiments 33-40, wherein the subject is a pediatric patient.
[0154] Embodiment 43: The pharmaceutical composition of any one of embodiments 33-42, wherein the pharmaceutical composition is formulated for administration by a flat dosing regimen.
[0155] Embodiment 44: The pharmaceutical composition of any one of embodiments 33-42, wherein the pharmaceutical composition is formulated for administration by a loading dose regimen.
[0156] Embodiment 45: The pharmaceutical composition of any one of embodiments 33-44, wherein the pharmaceutical composition comprises nemolizumab.
[0157] Embodiment 46: The pharmaceutical composition of any one of embodiments 33-45, further comprising an anti-inflammatory drug or an immunosuppressive drug.
[0158] Embodiment 47: The pharmaceutical composition of embodiment 46, wherein the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID).
[0159] Embodiment 48: The pharmaceutical composition of embodiment 46, wherein the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.Equivalents
[0160] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs. The present technology illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising,” “including,” “containing,” etc. shall be-40- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the present technology claimed.
[0161] Thus, it should be understood that the materials, methods, and examples provided here are representative of various aspects, are exemplary, and are not intended as limitations on the scope of the present technology.
[0162] The present technology has been described broadly and generically herein. Each of the narrower species and sub-generic groupings falling within the generic disclosure also form part of the present technology. This includes the generic description of the present technology with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.EXAMPLESExample 1: Evaluating nemolizumab in subjects with systemic sclerosis
[0163] Subjects: Select subjects diagnosed with systemic sclerosis for at least 6 months and with a modified Rodnan skin score (mRSS) of at least 8, at least 12 or at least 15.
[0164] Dosage and Administration: For subjects weighing less than 90 kg, administer 70- 109 mg of nemolizumab. For subjects weighing equal to or more than 90 kg, administer 110-140 mg of nemolizumab.
[0165] Administer nemolizumab subcutaneously once every four weeks or every eight weeks.
[0166] Duration: Between about 4 (four weeks after the first administration) to 52 weeks (four weeks after the last administration). Treatment duration is defined as the period up to 4 weeks after an injection.-41- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0167] Assessment: Measure the mRSS at baseline and at the end of the treatment period to evaluate changes in skin thickness.Example 2: Evaluating doses of nemolizumab for systemic sclerosis
[0168] Subjects: Select subjects diagnosed with systemic sclerosis for at least 6 months and with a modified Rodnan skin score (mRSS) of at least 15.
[0169] Dosage and Administration:Group A: Administer 30-60 mg of nemolizumab subcutaneously once every four weeks.Group B: Administer 90-120 mg of nemolizumab subcutaneously once every eight weeks.
[0170] Duration: Between about 4 (four weeks after the first administration) to 52 weeks (four weeks after the last administration). Treatment duration is defined as the period up to 4 weeks after an injection..
[0171] Assessment: Measure the mRSS at baseline, mid-treatment, and at the end of the treatment period to evaluate changes in skin thickness.Example 3: Nemolizumab dose selection in patients with SSc
[0172] Exposure of nemolizumab decreases with increasing body weight. Tiered fixed dosing was used with a 90 kg body weight cutoff to define patient strata that receive different flat doses. Tiered fixed dosing was used to achieve matching systemic exposure in patients with body weight < 90 kg and > 90 kg.
[0173] For Low dose trials, dose was based on the dosing regimen already used in patients with Prurigo nodularis (PN). Low dose regimen comprises a 60 mg loading dose, followed by 30 mg administrations with 60 mg dose adjustment for subjects with body weight over 90kg.
[0174] High dose is selected to reduce the overlap with inter-individual variability of the lower dose. High dose regimen comprises a 90 mg loading dose, followed by 90 mg administrations with 120 mg dose adjustment for subjects with body weight over 90kg.-42- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0175] Low dose and high dose nemolizumab steady state serum concentrations are shown in FIGs 1 and 2 and Table 1 below. Clinical study objectives and design are summarized in FIG. 3
[0176] Table 1Example 4: Clinical Study of nemolizumab in subjects with systemic sclerosis
[0177] SSc is a rare autoimmune, inflammatory and progressive multisystem connective tissue disease (CTD). SSc is characterized by small vessel vasculopathy and abnormal collagen deposition, leading to fibrosis of the skin and internal organs. Chronic vascular injury, endothelial activation, and immune activation are all thought to be crucial for secondary fibroblast activation and related fibrogenesis.
[0178] Preclinical evidence suggests a pathogenic role for IL-31 signaling in driving skin fibrosis in models of systemic fibrosis (SSc) and idiopathic pulmonary fibrosis (IPF).
[0179] Overall, patients with SSc could benefit from treatment with nemolizumab due to its anti-inflammatory and antifibrotic effects. The primary hypothesis of the study is that nemolizumab will be effective in systemic sclerosis (SSc), i.e., skin fibrosis and SSc-associated interstitial lung disease (SSc ILD).
[0180] Major Disease Subsets:-43- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0181] Based on the extent of skin involvement and the accompanying pattern of internal organ involvement including the presence of overlapping features with other systemic rheumatic diseases, systemic sclerosis is classified into 3 major subsets, with the majority of patients in 2 categories (described below) which will be included in this study.
[0182] Limited cutaneous systemic sclerosis (IcSSc): Patients with IcSSc have prominent vascular manifestations, including severe RP and mucocutaneous telangiectasia, and is characterized by slow progression often complicated by pulmonary hypertension (PH).Patients generally develop skin sclerosis distal to the elbows and knees, and, to a lesser extent, the face and neck, and may also have gastroesophageal reflux disease. Many patients with IcSSc have manifestations of the CREST syndrome (calcinosis cutis, RP, esophageal dysmotility, sclerodactyly, and telangiectasia).
[0183] Diffuse cutaneous systemic sclerosis (dcSSc): In addition to having RP, patients with dcSSc are more likely to have internal organs involved, particularly the lung, heart, and kidneys, as well as the gastrointestinal (GI) tract. Patients generally present with puffy hands and develop skin thickening extending proximally to the upper arms, thighs, and / or trunk. This type is typically characterized by a rapid progression of skin thickening with early development of ILD, scleroderma renal crisis (SRC) and cardiac disease.
[0184] The other subset of systemic sclerosis is sine scleroderma, which is rare, and patients have systemic sclerosis-related antibodies and visceral manifestations of the disease but no skin tightening.
[0185] Benefit Assessment:
[0186] SSc presents significant unmet medical needs due to its complex and multifaceted nature. There are no FDA approved therapies for SSc (only 2 approved therapies exist for SSc ILD i.e., tocilizumab, nintedanib), and off-label treatments aim to manage symptoms, slow disease progression, and address specific organ involvement. There is a need for the development of disease-modifying therapies that can halt or reverse disease progression. This includes targeting the underlying mechanisms of fibrosis, vascular damage, and immune dysregulation, such as antifibrotic agents, immunomodulators, and therapies targeting-44- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021specific molecular pathways implicated in SSc. It is suggested that SSc patients could benefit from treatment with nemolizumab due to the following:• High unmet medical need• Preclinical evidence for efficacy in SSc lung and skin• Anti-fibrotic efficacy of nemolizumab proven in the PN patients (i.e. skin lesion’s fibrosis improvement)• From a mechanistic point of view, treatment with nemolizumab may also be beneficial on the disease including lung and other organs, for example, skin.• Supportive safety data from thousands of participants use in other indications, including PN and AD.
[0187] Subjects: Select subjects diagnosed with systemic sclerosis for at least 6 months and with a modified Rodnan skin score (mRSS) of at least 8, at least 12 or at least 15.
[0188] Dosage and Administration: Participants will be randomized to receive SC injection of different nemolizumab doses according to their body weight i.e. 30 mg, 60 mg, 90 mg or 120 mg for up to 52 weeks. Dosage may vary for subjects weighing less than 90 kg relative to subjects weighing equal to or more than 90 kg.
[0189] Of note, the maximal approved dose regimen for AD and PN indications is a 60 mg dose for up to 48 weeks.
[0190] Nemolizumab will be administered subcutaneously once every four weeks.
[0191] Study Design:
[0192] This is a 52-week, Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 3 -arm study.
[0193] Participants will be randomized in a 1:1:1 ratio. Randomization will be stratified by background therapy (with or without mycophenolate i.e., MMF / MPS / MPA) and SSc ILD-45- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021(with or without SSc ILD based upon central reading). SSc ILD is expected to comprise approximately 60% of the total study participants, confirmed by HRCT central reading.
[0194] Participants will receive SC injections of 2 doses of nemolizumab or matching placebo Q4W:
[0195] Dose 1:• Participants weighing <90 kg: 30 mg Q4W with 60 mg loading dose at BL• Participants weighing >90 kg: 60 mg Q4W
[0196] Dose 2:• Participants weighing <90 kg: 90 mg Q4W with 120 mg loading dose at BL• Participants weighing >90 kg: 120 mg Q4W
[0197] Participation in the study will be up to 68 weeks. The study consists of a screening period (up to 8 weeks), a 52-week treatment period, and an 8-week follow-up period (12 weeks after the last study treatment).
[0198] All participants will be eligible for rescue therapy when disease progression occurs compared to BL values, i.e., Disease progression is defined as:• 1. Decrease from BL in ppFVC >10%; or in established ILD participants as confirmed by 2 consecutive monthly visit measurements; or• 2. Decrease from BL in ppFVC >5% plus decrease in ppDLCO >5% confirmed by 2 consecutive monthly visit measurements; or• 3. Increase from BL in mRSS by >5 points and a percent increase >25% in mRSS from BL.
[0199] Participants with disease progression will be eligible for rescue therapy at the investigator’s discretion. Rescue therapy may include, but is not limited to new-46- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021immunosuppressive therapy (1ST) (i.e., Cyclophosphamide, Rituximab, Tocilizumab); or increased dose of allowed background methotrexate, mycophenolate or nintedanib.Participants should be kept in the study after the intake of rescue therapies and should follow the visit schedule, if possible.
[0200] Participants with disease progression and started with rescue therapies are considered as treatment failure.
[0201] Inclusion Criteria:
[0202] Participants are eligible to be included in the study only if all of the following criteria are fulfilled:
[0203] 1. Participant must be 18 years of age or older, at the time of signing the informed consent.
[0204] 2. Classification of SSc as defined by the 2013 American College of Rheumatology [ACR] / European League Against Rheumatism [EULAR] criteria.
[0205] 3. Disease duration in:a. DcSSc participants ≤5 years from screeningb. LcSSc participants ≤2 years from screening
[0206] Disease duration is defined as the time from the first non-Raynaud’s phenomenon manifestation of SSc.
[0207] 4. Modified Rodnan Skin Score:a. DcSSc participants and modified Rodnan Skin Score (mRSS) of >12 and <30 at both screening and baselineb. LcSSc participants with mRSS >8 at both screening and baseline. LcSSc participants with positive anti-centromere at screening are excluded.-47- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0208] 5. Participants are permitted to receive the following background therapies stable for at least 3 months prior to baseline, including any combination of the following:a. Nintedanib (<150mg twice daily) and / orb. One of the following:1) Methotrexate (MTX) (<25mg weekly) or2) Mycophenolate mofetil (MMF), mycophenolate sodium (MPS), or mycophenolic acid (MPA) (<3000mg daily MMF, <2160mg daily for MPS or MPA)
[0209] NOTE: MTX should not be used in combination with MMF / MPS / MPA
[0210] 6. Participants should meet:a. Early disease duration (≤18 months at screening, defined as time from the first non-Raynaud phenomenon manifestation)b. OR if disease duration is >18 months, at least two of seven the following criteria at screening (anti-RNA polymerase 3 antibody positive for participants with a disease duration of >18 months are excluded):1) Two new body areas within the previous 6 months2) Increase in mRSS of ≥ 3 units compared with the most recent assessment performed within the previous 6 months3) Involvement of one new body area and an increase in mRSS of ≥2 units compared with the most recent assessment performed within the previous 6 months4) Tendon friction rub documented by medical records within 3 months or presence of arthritis or tenosynovitis not explainable by other causes other than SSc5) CRP ≥ 0.6 mg / dL (≥ 6 mg / L) or ESR ≥ 28 mm / hr.-48- 4915-2894-6601.1Atty. Dkt. No.: 105153-100216) SSc-ILD (confirmed by HRCT central reading) or Anti-topoisomerase I autoantibodies (anti-Scl-70) positive (> 20 U / mL) 7) mDAI > 2.5
[0211] 7. Men (whose female partner can become pregnant) and women of childbearing potential will be required to use effective means of contraception or commit to true abstinence, when this is in line with preferred and usual lifestyle of the participant, during the study and for at least 12 weeks after receiving the last study treatment.
[0212] 8. Female participants of non-childbearing potential must meet 1 of the following criteria:a. Absence of menstrual bleeding for 1 year prior to screening without any other medical reason. For women under 60, postmenopausal status should be confirmed by a follicle-stimulating hormone (FSH) level >40 IU / L, while no FSH confirmation is needed for women over 60.b. Documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 months before screening.
[0213] 9. Signed informed consent.
[0214] 10. Participant is willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol, including use of an electronic eCOA / ePRO type device.
[0215] Exclusion Criteria:
[0216] Participants are excluded from the study if any of the following criteria apply:
[0217] Laboratory Parameters
[0218] 1. Anti-centromere antibody positive at screening for participants with LcSSc.
[0219] 2. anti-RNA polymerase 3 antibody positive for participants with a disease duration >18months-49- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0220] 3. Creatinine clearance <30 ml / min (calculated by Cockcroft-Gault formula)
[0221] 4. Positive serology results (hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HbcAb], hepatitis C [HCV] antibody with positive confirmatory test for hepatitis C virus [HCV] antibody with positive HCV RNA, or human immunodeficiency virus [HIV] antibody). Note: Participants with a positive HBcAb and a negative HBsAg can be included if the hepatitis B surface antibody is positive (considered immune after a natural infection).
[0222] Participants who are positive for HCV antibody and negative for HCV RNA may be enrolled. (In the event of rescreening, the serology tests results (e.g., HBV, HCV, HIV) from the previous screening can be used by the investigator to assess the eligibility of rescreened participants if those tests are performed within 8 weeks prior to the BL visit).
[0223] Lung Diseases
[0224] 5. FVC <50% of predicted normal value, and DLCO D40% of predicted normal value (corrected for Hb) at screening and baseline.
[0225] 6. Known diagnosis of clinically significant respiratory disorders other than ILD, including severe chronic obstructive pulmonary disease, severe asthma, recent (within 3 months) severe respiratory infections or history of recurrent respiratory infections, smoking, and any other respiratory condition that, in the opinion of the investigator, could interfere with the study or pose a risk to the participant.
[0226] 7. Currently listed and / or anticipated to be listed for lung transplantation within the next 12 months
[0227] Other Diseases
[0228] 8. Cardiovascular disease with clinically significant arrhythmia requiring therapy, congestive heart failure (New York Heart Association Class III-IV functional capacity), unstable angina, uncontrolled hypertension, Cor pulmonale, or symptomatic pericardial effusion.
[0229] 9. History of myocardial infarction in the last 6 months prior to screening.-50- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0230] 10. Pulmonary hypertension WHO Functional Class III or higher (as defined by WHO 2009) requiring treatment.(0231] 11. Clinical signs of severe malabsorption in the opinion of the investigator or needing parenteral nutrition
[0232] 12. History of SRC 6 months prior to screening
[0233] 13. Participants with underlying chronic liver disease (Child Pugh A, B, C hepatic impairment)
[0234] Other General Exclusion Criteria
[0235] 14. Body weight of <30.0 kg at screening or BL
[0236] 15. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed, or unwilling to use appropriate contraception measures during the study period
[0237] 16. Previous treatment with nemolizumab
[0238] 17. Participants with the primary diagnosis of a rheumatic autoimmune disease other than SSc, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis, systemic vasculitis, Sjogren’s syndrome, anti-synthetase syndrome, or mixed CTD, as determined by the investigator with consultation of the medical monitors
[0239] 18. Systemic sclerosis-like illness including but not limited to localized scleroderma (morphea), eosinophilic fasciitis, sclerodermoid graft-versus-host disease, fibro mucinous conditions (scleredema, scleromyxedema), scleroderma-like conditions that are associated with environmental chemical and drug exposure (e.g., toxic rapeseed oil, vinyl chloride, bleomycin, gadolinium-based contrast agents [nephrogenic systemic fibrosis], or due to metabolic disease)-51- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0240] 19. History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the study treatment excipient
[0241] 20. Known active bacterial, viral, fungal, or any major episode of infection requiring hospitalization or treatment with IV antibiotics or antivirals within 4 weeks prior to screening, or oral antibiotics within 2 weeks prior to screening. Participants may be rescreened once the infection has resolved.
[0242] 21. History of a primary immunodeficiency
[0243] 22. History of Bone Morrow Transplantation. Chimeric Antigen Receptor (CAR)-T Cell Therapy or any other genetically engineering cells
[0244] 23. History of lymphoproliferative disease or history of malignancy of any organ system within the last 5 years, except for (1) basal cell carcinoma, squamous cell carcinoma in situ (Bowen’s disease), or carcinomas in situ of the cervix that have been treated and have no evidence of recurrence in the last 12 weeks before the BL visit, or (2) actinic keratoses that have been treated
[0245] 24. History of alcohol or substance abuse dependence or any condition that, in the investigator’s opinion makes the participant unreliable to following instructions and complete the study
[0246] 25. In the opinion of the investigator, the participant has any medical condition, including clinically significant pulmonary abnormalities, or psychological condition, or clinically significant laboratory abnormalities that could pose undue risk to the participant, prevent study completion or adversely affect the validity or interpretability of the study measurements or interfere with the study assessments, or impede the participant’s ability to complete the study.
[0247] Study Treatment Administered:
[0248] The Nemolizumab 30mg DCC-AI is a single-use (disposable), single-dose, autoinjector containing lyophilized monoclonal antibody – Nemolizumab, and Water for Injection-52- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021(WFI). Nemolizumab and its diluent (WFI) are stored in separate chambers of the dual-chamber cartridge (DCC) and remain separated by a rubber plunger prior to mixing.Nemolizumab is stored in the front chamber (chamber 1) and WFI in the rear chamber (chamber 2).
[0249] Participants will receive an initial dose of nemolizumab or placebo by 4 SC injections at BL while Post-BL, participants will receive nemolizumab or placebo by SC injections (3 injections for participants weighing <90 kg, 4 injections participants weighing >90 kg) Q4W for the rest of the treatments, last dose will be received at Week 48. See table below.
[0250] Participants will be followed up until Week 60.
[0251] IP administration will occur at the study site.
[0252] At the BL visit, the investigator or designee will inject the IP and will provide training for participants (and / or caregiver) willing and able to self-inject. (or have their caregiver inject) IP at post-BL visits. Based on the participant’s preference, study center staff can perform injections.-53- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0253] Instructions will be provided in the instructions for use document and the pharmacy manual. IP will be administered after clinical procedures and blood collection. There must be at least 21 days between study drug administration.
[0254] The investigator or designee should train the participant to recognize potential signs and symptoms of hypersensitivity reaction so they can self-monitor for at least 30 minutes post-dose (or longer per country or local site-specific requirements).
[0255] Efficacy Assessment:
[0256] Modified Rodnan Skin Score
[0257] The assessment of skin involvement includes semiquantitative estimation of skin thickness, pliability (hardness), and fixation to underlying structures (tethering). The mRSS is commonly used as an outcome measure in clinical studies and meets the OMERACT (Outcome Measures in Rheumatology) criteria as a fully validated measure of outcome. This is a validated physical examination method for estimating skin induration by pinching the skin into a fold. This measurement of skin thickness has been correlated with prognosis and visceral involvement, especially in early disease. It is a static assessment. Scoring of each individual cutaneous area is semiquantitative and is scored on a scale of 0 to 3, where mRSS of score 0 is defined as “normal” with fine wrinkles but no skin thickness; mRSS of score 1 is defined as definite but “mild” skin thickness; mRSS of score 2 is defined as “moderate” skin thickness with difficulty in making skin folds and no wrinkles; and mRSS of score 3 is defined as “severe” skin thickness with inability to make skin folds between 2 examining fingers. mRSS is assessed in 17 different body areas.
[0258] To ensure consistency and accuracy in mRSS assessments and reduce inter-assessor variability, only those physicians or qualified medical personal who have been undergone a standard training will be permitted to assess the skin thickening. Every effort will be taken for the same trained and certified assessor to evaluate each participant throughout the study. In the unlikely event of the assessment being carried out by different personnel, the reason will be documented. The baseline and Week 52 mRSS assessment must be conducted by the same-54- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021medical personnel. The mRSS Assessor’s Qualification and Training Guide will provide further details.
[0259] To minimize bias, assessors will avoid reviewing prior mRSS scores and will not ask participants to comment on perceived changes since the last visit. Participants will be instructed to refrain from applying moisturizers or cosmetics on the day of assessment to ensure accurate palpation and scoring.
[0260] Forced Vital Capacity
[0261] FVC will be assessed with the FlowScreen® spirometer, which will be supplied to all participating sites. Central reading will be conducted along the 2019 American Thoracic Society (ATS) / European Respiratory Society (ERS) Guideline. Spirometry measurements must be performed according to ATS / ERS 2019 guideline. Spirometry will be conducted while the participant is in a seated position. The test will be done in triplicate (3 curves to be provided), and the best result selected according to the guidelines. Spirometry results captured by spirometers provided by the sponsor will be electronically transmitted and confirmed by central reading. The ATS / ERS / ATS 2019 guideline will be referenced for spirometry.
[0262] Feedback will be provided to investigators about unacceptable readings.
[0263] The best of 3 efforts will be defined as the highest FVC, obtained on any of the 3 blows meeting the ATS / ERS criteria with preferably a maximum of 5 maneuvers.
[0264] For each participant, the spirometric measurements will always start at approximately the same time of the day (with ± 90 minutes maximum difference, time will be recorded), with reference to BL measurement (Visit 2).
[0265] On days of clinic visits, participants must refrain from strenuous activity at least 12 hours prior to pulmonary function testing. Smoking should be discouraged throughout the visit days (clinic visit) and will not be permitted in the 30-minute period prior to spirometry. Participants should also avoid cold temperatures, environmental smoke, dust, or areas with-55- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021strong odors (e.g., perfumes). If treated with bronchodilators, washout of 24 hours for long-acting and 8 hours for short-acting bronchodilators should be observed before spirometry.
[0266] Revised American College of Rheumatology Combined Response Index in Systemic Sclerosis
[0267] The rCRISS was developed to more effectively quantify in a single composite score the changes in the clinical and patient-reported outcomes associated with improvement in patients with early dcSSc. The assumption for an effective treatment for dcSSc is that participants treated with the applicable pharmacologic agent will have a higher probability of improvement as summarized by rCRISS vs. placebo or an ineffective agent. It includes core items that evaluate change in 2 common and prominent manifestations of early dcSSc (skin and ILD), functional disability (as assessed by the HAQ-DI), and PGA and CGA.
[0268] Carbon Monoxide Diffusion Capacity
[0269] The site will use its own DLCO equipment and conduct all measurements with the same DLCO equipment (e.g., if several devices would be available at the site). Single-breath DLCO will be carried out according to the 2017 ERS / ATS guideline on DLCO measurements. DLCO and the corresponding alveolar volume will be measured at time points given in the SoA (section 1.3). Before beginning the test, the maneuvers should be demonstrated and the participant carefully instructed.
[0270] The manual correction of DLco for hemoglobin will be based upon the following equation unless it is automatically corrected during measurement:• For male patients: DLcoobserved / (factor), where factor is = (1.7 x Hb) / (10.22 + Hb)• For female patients: DLcoobserved / (f actor), where factor is = (1.7 x Hb) / (9.38 + Hb)
[0271] Note: Hb = Hemoglobin. The value of hemoglobin will be taken from the same visit where the DLco is conducted.-56- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0272] In any case, the calculation method used must be compliant with the ERS / ATS guideline on DLCO measurements and the prediction formula appropriate for that method. Raw data (gas mixture, equation used for prediction of normal, further adjustments made if so) must be traced.
[0273] The DLCO assessment should always be performed after the FVC assessment and should always be started approximately at the same time a day, i.e., with ± 90 minutes maximum difference between start of the tests at BL (Visit 2). FVC and DLCO tests are needed to be confirmed across 2 consecutive visits defined by disease progression.
[0274] High-Resolution Computed Tomography
[0275] The HRCT will be performed. A screening HRCT is only required for participants who do not have one conducted within the past 12 months prior to screening.
[0276] If the participant has a prior HRCT scan that meets the 12-month criteria upon central review and the participant is clinically stable for screening, it can be used for baseline without repeating imaging. A participant can be considered clinically stable when all the following conditions are satisfied:• The participant has not experienced new or worsening respiratory symptoms since the prior scan.• There hasn’t been any significant change in PFTs (e.g., >10% decline in FVC or >10% decline in DLCO).• No treatment adjustments are being considered based on progression risk or response evaluation.
[0277] If the participant does not have a HRCT within the previous 12 months at screening, but meets all other inclusion and no exclusion criteria, the HRCT should be performed. For the purposes of participation in the study.
[0278] Patient’s Global Assessment and Clinician / Physician’s Global Assessment-57- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021(0279] The participant’s global impression of health Numeric Rating Scale 0-10 (NRS) will be self-administered by the participant at visits indicated in the SoA. 0 represents excellent and 10 represents extremely poor.
[0280] The clinician / physician’s global impression of health Numeric Rating Scale 0-10 (NRS) will be filled out by the participant’s clinician / physician at visits outlined in the SoA after all other study procedures have been completed. 0 represents excellent and 10 represents extremely poor.
[0281] Health Assessment Questionnaire Disability Index
[0282] HAQ-DI is a participant-reported questionnaire and sensitive to change in disease activity (cutaneous and visceral involvement and with changes in physiological parameters over time). It is part of the rCRISS evaluation. HAQ-DI covers 20 items in 8 domains related to measuring difficulty in performing activities of daily living: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each question is rated on a 0 to 3 scale (0 = without difficulty; 3 = unable to do), and additional points can be added if aids or devices (i.e., cane, walker) are needed for specific activities. An increased score indicated worse functionality. Evaluation should be performed before the physical examination of the specified study visit. HAQ-DI score corresponds to the sum of the subscores of all 8 categories divided by the number of categories completed. This provides a score between 0 and 3 on an ordinal scale (no disability to severe disability). A high score corresponds to worse impairment.
[0283] EuroQoL 5-Dimension 5-Level
[0284] The EuroQoL 5-dimension 5-level (EQ-5D-5L) questionnaire comprises 5 dimensions:• Mobility• Self-care• Usual activities-58- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021• Pain / discomfort• Anxiety / depression
[0285] Each dimension has 5 levels:• No problems• Slight problems• Moderate problems• Severe problems• Extreme problems
[0286] The participant is asked to indicate his / her health state by ticking the box next to the most appropriate statement in each of the 5 dimensions. This decision results in a 1 -digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the participant’s health state.
[0287] The participant’s health state can be converted into a single number called index value. The index value reflects how good or bad the health state is according to the preferences of the general population of a country / region. The collection of index values for all possible participant’s health states is called a value set. Value sets are currently available for the EQ-5D-5L for different countries / regions.
[0288] European Alliance of Associations for Rheumatology Systemic Impact of Disease Questionnaire
[0289] The EULAR ScleroID questionnaire is as a global measurement tool to assess the disease burden in SSc patients (Becker 2022). The ScleroID questionnaire covers the following 10 health dimensions: Raynaud’s phenomenon, hand function, upper GI symptoms, pain, fatigue, lower GI symptoms, limitations of life choices and activities, body mobility, breathlessness, and digital ulcers.-59- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0290] The questionnaire is simple and easy to apply, has high internal consistency and shows good correlation with the PGA and the HAQ-DI. The ScleroID questionnaire has a very good retest reliability, which is even better than comparators and has better sensitivity to change than the comparators used. This is especially important as a high percentage of patients are relatively stable, but progression of the disease drives mortality and morbidity.
[0291] The EQ VAS records the participant’s self-rated health on a vertical visual analog scale, where the endpoints are labeled ‘The best health you can imagine’ and ‘The worst health you can imagine’. The VAS can be used as a quantitative measure of health outcome that reflect the participant’s own judgment.
[0292] Oxygen Saturation
[0293] Oxygen saturation (SpO2) will be measured at rest by standard pulse oximetry (unaffected skin of earlobe or forehead) and the recorded value will be entered in the eCRF.
[0294] Digital Ulcers
[0295] Net ulcer burden is defined as the number of new digital ulcers plus the number of digital ulcers that have been verified at any earlier assessment during the study.
[0296] A digital ulcer is defined as an area of loss of continuity of both epithelial coverage and of part of the dermal tissue. If covered by a scab and there is no debridement performed, the decision whether there is an ulcer with loss of continuity of both epithelial coverage and part of the dermal tissue is by investigator’s clinical judgment. Only digital ulcers distal to the proximal interphalangeal joints and vascular in origin are assessed.
[0297] Digital ulcer net burden will be assessed by counting total number of digital ulcers at the timepoints indicated in the SoA. The absolute change is calculated by counting of ulcers at timepoint minus number of ulcers at BL.
[0298] Disease Progression
[0299] Disease progression is defined as:-60- 4915-2894-6601.1Atty. Dkt. No.: 105153-100211. Decrease from BL in ppFVC >10%; or in established ILD participants as confirmed by 2 consecutive monthly visit measurements; or2. Decrease from BL in ppFVC >5% plus decrease in pp DLCO >15% confirmed by 2 consecutive monthly visit measurements; or3. Increase from BL in mRSS by >5 points and a percent increase >25% in mRSS from BL.
[0300] Participants with disease progression will be eligible for rescue therapy at the investigator’s discretion. Rescue therapy may include: new immunosuppressive therapy (1ST) medications (i.e., Cyclophosphamide, Rituximab, Tocilizumab); or increased dose of allowed background methotrexate, my cophenolate or nintedanib.
[0301] Participants with disease progression and intake of rescue therapies are considered as treatment failure.
[0302] PROMIS Dyspnea Characteristics
[0303] The PROMIS Dyspnea Characteristics item pool is a collection of items that assess various descriptive aspects of a participant’s experience of dyspnea. This includes both quantitative and qualitative descriptions of the severity and intensity of shortness of breath as well as its frequency and duration. Items use assess dyspnea characteristics over the past 7 days. There are 5 items in the item pool.
[0304] Patient’s Global Impression of Severity 6 Items
[0305] PGI-S 6 items includes: severity of skin thickness, severity of shortness of breath, ability to perform physical activities, the effect of systemic sclerosis, severity of upper gastrointestinal tract symptoms, severity of lower gastrointestinal tract symptoms over 7 days.
[0306] Short Form-36 Health Survey
[0307] SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon participant self-reporting.-61- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0308] Clinical Photography
[0309] The objective is to provide supplemental evidence to the clinical assessment of the skin sclerodactyly or digital ulcers if applicable.
[0310] Five to 10 selected sites will participate in clinical photography, i.e. photos will be taken for each consented participant at the timepoints of mRSS assessments at these sites. Declining to participate in this part of this study will not affect participants’ involvement in the main part of the study. Equipment for clinical photography will be provided to those participating sites and details on the photography procedures will be outlined in the photography manual.
[0311] Skin Biopsy
[0312] Skin biopsy is optional. Skin will be assessed to investigate the transcriptomic changes induced upon nemolizumab treatment. To this aim, 3-mm punch biopsy will be taken at BL and week 52 as indicated in the Schedule of Assessment of Optional Substudies. The detail of the analysis process will be described in the biomarker analyses plan, which will be finalized before the beginning of sample analysis.
[0313] Qualitative Exit Interview
[0314] A qualitative exit interview will be conducted in a subset of the participant population at Week 52 to assess the participant’s experience during the study. The purpose of the qualitative exit interview is to gather insights to inform the interpretation and clinical meaningfulness of the primary and secondary endpoints. Interview topics will cover participants’ experience with the disease, such as associated symptoms, symptom impact / burden, interference on the participant’s life, symptom / impact changes during the study, participant perceptions of meaningful changes and to explore participant experience with treatment.[03151 The interviews will explore whether the concepts measured in the study are important and meaningful to participants and whether any important symptoms or impacts have not been captured in the study. The interview will consist of a one-time telephone / video-62- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021interview via MS Teams, lasting approximately 60 minutes. During the interviews, participants will be asked to complete a set of pre-interview questions about their symptoms and impacts which will be captured electronically. The participant’s responses to the preinterview survey will be used to probe the participants responses in more detail during the interview to better understand the nature of the change and rationale for why the change was or was not meaningful to them. Interviews will be conducted by trained interviewers using a semi-structured interview guide and will be conducted within 7 days of completing the Week 52 visit. Neither failure to complete the interview nor completion outside the targeted 7-day window will constitute a protocol deviation. All participants enrolling in the study will be invited to participate in the qualitative interview until the targeted subsample of 30-40 participants have been filled. This sample is large enough to accomplish objectives.
[0316] Modified EUSTAR DAI
[0317] The Modified EUSTAR Disease Activity Index (mDAI) is a clinical tool used to assess the disease activity in SSc (Valentini G et al 2017; Herrick et al 2023). The mDAI based on modified Rodnan skin score (mRSS), C-reactive protein (CRP) level, diffusing capacity of the lung for carbon monoxide (DLco), presence of digital ulcers, presence of tendon friction rubs, and worsening of skin fibrosis over the previous month (as assessed by the patient). A score >2.5 identifies patients with active / very active vs inactive / moderately active disease. The assessment will be completed at screening, BL, Week 24 and Week 52.-63- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0318] Safety Assessments
[0319] Physical Examinations
[0320] A complete physical examination (PE) will include, at a minimum, assessments of the head, ears, eyes, nose, throat, neck (including thyroid), skin / integumentary system, cardiovascular system, respiratory system, GI system, musculoskeletal system, lymph nodes, nervous system, and extremities. Complete physical examinations will be performed at the timepoints specified in the SoA.
[0321] The complete PE is required at Baseline, Wkl2, Wk24, Wk36, Wk52, and Wk60. Targeted, short PEs may be performed at other visits (scheduled or unscheduled) at the investigator's discretion, as needed. Discretionary assessments, based on the investigator’s clinical judgment, would focus on essential safety monitoring. These may include, but are not limited to, examination of body systems related to any reported adverse events reported.
[0322] Height and weight will also be measured and recorded according to the SoA.
[0323] The investigator must assess all abnormal findings for clinical significance. Clinically significant abnormal findings at the screening visit will be recorded as medical history.Clinically significant changes from the screening visit will be recorded as an AE.
[0324] Vital Signs
[0325] Vital signs will be measured in a sitting position, after 5 minutes rest and will include temperature, systolic and diastolic blood pressure, respiration rate and pulse rate. Vital signs will be recorded at the timepoints specified in the SoA.
[0326] The investigator must assess all abnormal values for clinical significance. Clinically significant abnormal findings at the screening visit will be recorded as medical history.Clinically significant changes from the screening visit will be recorded as an AE.
[0327] Vital signs at Week 52 and at Week 60 (end-of-study treatment and participant’s last visit) should be performed for all participants. Permission to contact withdrawn participants for vital signs assessment should be requested by site.-64- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0328] Electrocardiograms
[0329] Single 12-lead ECG will be obtained using an ECG machine that automatically calculates the heart rate and measures QRS, PR, RR, QT, QTcB and QTcF intervals. ECG will be performed at screening and if abnormal repeat at BL prior randomization.
[0330] Local results will be reported in the clinical database. The investigator must review the ECG results and assess for clinical significance. Clinically significant abnormal findings at the screening visit will be recorded as medical history. Clinically significant changes from the BL visit will be recorded as an AE. The ECG results must be retained with source documents.
[0331] ECGs will be obtained at the timepoints specified in the SoA. An ECG is not required at week 60 (follow-up) if participants have a normal ECG at week 52.
[0332] Pharmacokinetics
[0333] PK Blood Samples
[0334] Blood samples will be collected for measurement of serum concentrations of nemolizumab at the timepoints specified in the SoA.
[0335] At each sampling timepoint for PK assessments, the collected blood will be placed to clot at room temperature (no more than 60 minutes after collection) and then centrifuged. The serum will be collected into storage tubes.
[0336] As a guideline, PK samples should be collected at approximately the same time of day throughout the study, to the extent possible, before IP injection (pre-dose samples).
[0337] Detailed instructions for the collection and handling of biological samples will be provided in the sponsor clinical laboratory manual. The actual date and time (24-hour clock time) of each sample will be recorded.
[0338] Nemolizumab Quantification in Serum Samples-65- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0339] Concentration of nemolizumab in the serum will be determined by the designated contract research organization (CRO) using a validated enzyme-linked immunosorbent assay method. Details related to the quantification of nemolizumab concentrations in the PK samples will be described in the bioanalytical plan, which will be finalized before the beginning of sample analysis. Results will be described in the bioanalytical report, which will be included as an appendix in the final clinical study report.
[0340] Biomarkers
[0341] Skin biopsies and whole blood will be collected to investigate the effects of nemolizumab on RNA and protein biomarkers at the timepoints specified in the SoA. These biomarkers will be determined for exploratory research purposes. To avoid batch effects, samples will be kept at the central lab until the number of needed samples is obtained. We estimate this duration to a maximum of 2.5 years.
[0342] Skin Biopsies for Transcriptomics Analyses
[0343] A total of two 3 -mm punch biopsies will be taken from a lesional site identified on the forearm (only for participants who accept skin biopsies by signing the additional consent form) for RNA biomarkers. Biopsies should be collected according to the investigator’s usual procedure, including follow-up.
[0344] Skin biopsies will be performed as follows:• BL visit: One 3-mm punch biopsy on lesional skin in the forearm• Week 52 visit: One 3-mm punch biopsy designated lesional at baseline in the forearm skin, but at a different location from the one collected at BL.
[0345] After 52 weeks, the exact site designated as lesional at baseline will be sampled following the same protocol. Even though the site may have changed phenotypically by then and not be considered lesional any longer, its annotation as "lesional" will be maintained. Thus "lesional" in this context exclusively refers to the site’s phenotypic state at baseline. Photographs of the biopsy location should be taken prior to biopsy skin area both at BL and-66- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021at Week 52 and reported with the description of the lesional state of the skin area that will be collected. Instructions for Clinical Photography will be detailed the Photography Manual.
[0346] The details of the transcriptomics analysis process will be described in the biomarker analyses plan, which will be finalized before the beginning of sample analysis.
[0347] Whole Blood Samples for Transcriptomic Analyses
[0348] Whole blood samples will be collected in PAXgene® Blood RNA tubes. The details of the collection procedures and the storage conditions are further described in the clinical laboratory manual.
[0349] Samples will be sent to a designated CRO for RNA extraction and RNA-seq analyses to reveal transcriptomic changes induced by nemolizumab after 24 and 52 weeks of treatment. The details of the transcriptomic analysis process will be described in the biomarker analyses plan, which will be finalized before the beginning of sample analysis.
[0350] Plasma Samples for Proteomic Analyses
[0351] Blood samples will be collected in ethylenediaminetetraacetic acid (EDTA) tubes. The details of the collection, the plasma separation procedures and the storage conditions are further described in the clinical laboratory manual.
[0352] Samples will be sent to a designated CRO for proteomic analyses. IL-31 levels will be measured using a highly sensitive single-plex immunoassay. And in parallel, a panel of cytokines and chemokines (including but not restricted to TARC [thymus and activation regulated chemokine, CCL17], eotaxin 3 (CCL26), MDC (CCL22) (Macrophage-derived chemokine) will be measured using a sensitive multiplex immunoassay.
[0353] The detail of the proteomic analysis process will be described in the biomarker analyses plan, which will be finalized before the beginning of sample analysis.
[0354] Genetics-67- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021(0355] Whole blood will be collected at BL for genotyping analysis for all consenting participants. The detail of the genetic analysis process will be described in the biomarker analyses plan, which will be finalized before the beginning of sample analysis.
[0356] Immunogenicity Assessments
[0357] ADA Blood Samples
[0358] Blood samples will be collected for analysis of anti-drug antibodies (ADA) and neutralizing antibody (NAb) in serum at the timepoints specified in the SoA.
[0359] At each sampling timepoint for ADA / NAb assessments, the collected blood will be placed to clot at room temperature (no more than 60 minutes after collection) and then centrifuged. The serum will be collected into storage tubes.
[0360] As a guideline, ADA / NAb samples should be collected at approximately the same time of day throughout the study, to the extent possible, before IP injection (pre-dose samples).
[0361] Instructions for the collection and handling of biological samples will be provided in the clinical laboratory manual. The actual date and time (24-hour clock time) of each sample will be recorded.
[0362] ADA Assessment in Serum Samples
[0363] The ADA will be determined by the designated CRO using a validated electrochemiluminescence immunoassay (ECLIA). The serum concentration will be assessed using a multi-tiered approach.
[0364] If serum circulating ADA are detected, presence will be confirmed and characterized (e.g., for titer and neutralizing potential).
[0365] Details related to the assessments of ADA and NAb will be described in bioanalytical plans, which will be finalized before the beginning of sample analysis. Results will be-68- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021described in the bioanalytical reports, which will be included as an appendix in the final clinical study report.
[0366] Analysis Supporting Primary Objectives
[0367] Change from BL in mRSS at Week 52 will be analyzed using an analysis of covariance (ANCOVA) with treatment, background therapy (with or without MMF / MPS / MPA), SSc ILD (with or without SSc ILD), and baseline body weight (□90 kg, □90 kg) as factors and baseline mRSS as covariate. The least-square mean (LSM) estimate and the corresponding 95% CI will be estimated for the treatment effect, p-value for the treatment comparison will be derived from the regression model.
[0368] Missing data for the primary endpoint will be imputed using multiple imputation (MI) under missing at random (MAR) assumption
[0369] Change from BL in mRSS will be analyzed using a mixed model for repeated measures (MMRM) analysis under MAR assumption.
[0370] The primary analysis will be repeated by imputing missing data using a copy reference (CR) approach under missing not at random (MNAR) assumption.
[0371] Tipping point analysis using the delta-adjustment MI framework under MNAR assumption will be performed.
[0372] As supplementary analyses for the primary endpoint, MI under MAR, MMRM under MAR, CR under MNAR, and tipping point analysis using the delta-adjustment multiple imputation framework under MNAR will be repeated for the main supplementary efficacy estimated based on treatment policy. Moreover, the primary analysis for the primary endpoint will be repeated in the PP population.
[0373] Analyses Supporting Other Secondary Objectives
[0374] Change from BL in FVC at Week 52 will be analyzed using an ANCOVA with treatment, background therapy (with or without MMF / MPS / MPA), SSc ILD (with or without SSc ILD), and baseline body weight (<90 kg, >90 kg) as factors and baseline FVC, age, sex-69- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021and height as covariates. The LSM estimate and the corresponding 95% CI will be estimated for the treatment effect, p-value for the treatment comparison will be derived from the regression model.
[0375] Proportion of responders to the treatment at Week 52 based on rCRISS will be analyzed using the Cochran-Mantel-Haenszel test stratified by background therapy (with or without MMF / MPS / MPA) and SSc ILD (with or without SSc ILD).
[0376] Change from BL in mRSS at Week 24 will be analyzed using an ANCOVA with treatment, background therapy (with or without MMF / MPS / MPA), SSc ILD (with or without SSc ILD), and baseline body weight (D90 kg, D90 kg) as factors and baseline mRSS as covariate. The LSM estimate and the corresponding 95% CI will be estimated for the treatment effect, p-value for the treatment comparison will be derived from the regression model.
[0377] Percent change from BL in mRSS at Week 52 will be analyzed using an ANCOVA with treatment, background therapy (with or without MMF / MPS / MPA), SSc ILD (with or without SSc ILD), and baseline body weight (<90 kg, >90 kg) as factors and baseline mRSS as covariate. The LSM estimate and the corresponding 95% CI will be estimated for the treatment effect, p-value for the treatment comparison will be derived from the regression model.
[0378] Change from BL in ppFVC at Week 52 will be analyzed using an ANCOVA with treatment, background therapy (with or without MMF / MPS / MPA), SSc ILD (with or without SSc ILD), background therapies (with or without MMF / MPS / MPA), and baseline body weight (<90 kg, >90 kg) as factors and baseline ppFVC, age, sex, and height as covariates. The LSM estimate and the corresponding 95% CI will be estimated for the treatment effect, p-value for the treatment comparison will be derived from the regression model.
[0379] Percent change from BL in HAQ-DI at Week 52 will be analyzed using an ANCOVA with treatment, background therapy (with or without MMF / MPS / MPA), SSc ILD (with or without SSc ILD), and baseline body weight (□90 kg, □90 kg) as factors and baseline HAQ-DI score as covariate. The LSM estimate and the corresponding 95% CI will be estimated for-70- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021the treatment effect, p-value for the treatment comparison will be derived from the regression model.
[0380] Percent change from BL in PGA score at Week 52 will be analyzed using an ANCOVA with treatment, background therapy (with or without MMF / MPS / MPA), SSc ILD (with or without SSc ILD), and baseline body weight (□90 kg, □90 kg) as factors and baseline PGA score as covariate.
[0381] The LSM estimate and the corresponding 95% CI will be estimated for the treatment effect, p-value for the treatment comparison will be derived from the regression model.
[0382] Percent change from BL in CGA score at Week 52 will be analyzed using an ANCOVA with treatment, background therapy (with or without MMF / MPS / MPA), SSc ILD (with or without SSc ILD), and baseline body weight (□90 kg, □90 kg) as factors and baseline CGA score as covariate.
[0383] The LSM estimate and the corresponding 95% CI will be estimated for the treatment effect, p-value for the treatment comparison will be derived from the regression model.
[0384] Proportion of responders for mRSS at Week 24 and Week 52 will be analyzed using the Cochran-Mantel-Haenszel test stratified by background therapy (with or without MMF / MPS / MPA) and SSc ILD (with or without SSc ILD).
[0385] Proportion of responders for ppFVC at Week 52 will be analyzed using the Cochran-Mantel-Haenszel test stratified by background therapy (with or without MMF / MPS / MPA) and SSc ILD (with or without SSc ILD).
[0386] Change from BL ppDLCO corrected for hemoglobin at Week 52 will be analyzed using an ANCOVA with treatment, background therapy (with or without MMF / MPS / MPA), SSc ILD (with or without SSc ILD), and baseline body weight (□90 kg, □90 kg) as factors and baseline ppDLCO, age, sex, and height as covariates. The LSM estimate and the corresponding 95% CI will be estimated for the treatment effect, p-value for the treatment comparison will be derived from the regression model.-71- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021
[0387] Change from BL in ScleroID score at Week 52 will be analyzed using an ANCOVA with treatment, background therapy (with or without MMF / MPS / MPA), SSc ILD (with or without SSc ILD), and baseline body weight (<90 kg, >90 kg) as factors and baseline ScleroID score as covariate. The LSM estimate and the corresponding 95% CI will be estimated for the treatment effect, p-value for the treatment comparison will be derived from the regression model.
[0388] Time to treatment failure will be analyzed using Kaplan-Meier survival functions that will be compared between treatment groups by using the log-rank test.
[0389] Time to death will be analyzed using Kaplan-Meier survival functions that will be compared between treatment groups by using the log-rank test.-72- 4915-2894-6601.1
Claims
Atty. Dkt. No.: 105153-10021WHAT IS CLAIMED IS:
1. A method for treating systemic sclerosis, comprising administering to a subject with systemic sclerosis (a) at least 30 mg and up to 90 mg of nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 120 mg of nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg.
2. A method for treating systemic sclerosis, comprising administering to a subject with systemic sclerosis at least 30 mg and up 120 mg of nemolizumab or an equivalent thereof.
3. The method of claim 1 or 2, wherein the subject suffers from one or more, moderate to severe systemic sclerosis.
4. The method of any one of claims 1-3, wherein the systemic sclerosis is a diffuse scleroderma or a limited scleroderma.
5. The method of any one of claims 1-4, wherein the systemic sclerosis has been assigned a score of at least 15 on the modified Rodnan skin score (mRSS).
6. The method of any one of claims 1-5, wherein the nemolizumab or the equivalent thereof is administered by an enteric, a topical or a parenteral route.
7. The method of any one of claims 1-5, wherein the nemolizumab or the equivalent thereof is administered subcutaneously.
8. The method of any one of claims 1-7, wherein the nemolizumab or the equivalent thereof is administered once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once every eleven weeks.
9. The method of any one of claims 1-8, wherein the subject is an adult.
10. The method of any one of claims 1-8, wherein the subject is a pediatric patient.
11. The method of any one of claims 1-10, wherein the nemolizumab or equivalent thereof is administered according to a flat dosing regimen.-73- 4915-2894-6601.1Atty. Dkt. No.: 105153-1002112. The method of any one of claims 1-11, wherein the nemolizumab or equivalent thereof is administered according to a loading dose regimen.
13. The method of any one of claims 1-12, wherein the subject is administered nemolizumab.
14. The method of any one of claims 1-13, further comprising administering an effective amount of an anti-inflammatory drug or an immunosuppressive drug.
15. The method of claim 14, wherein the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID).
16. The method of claim 14, wherein the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.
17. Use of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of systemic sclerosis in a subject in need, wherein the medicament comprises a dosage of nemolizumab or an equivalent thereof that is (a) at least 30 mg and up to 90 mg nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or (b) at least 60 mg and up to 120 mg nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg.
18. Use of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of systemic sclerosis, wherein the medicament comprises a dosage of nemolizumab or an equivalent thereof that is at least 30 mg and up to 120 mg nemolizumab or an equivalent thereof.
19. The use of claim 17 or claim 18, wherein the subject suffers from one or more, moderate to severe systemic sclerosis.
20. The use of any one of claims 17-19, wherein the systemic sclerosis is a diffuse scleroderma or a limited scleroderma.
21. The use of any one of claims 17-18, wherein the systemic sclerosis has been assigned a score of at least 15 on the modified Rodnan skin score (mRSS).-74- 4915-2894-6601.1Atty. Dkt. No.: 105153-1002122. The use of any one of claims 17-21, wherein the medicament is formulated for administration by an enteric, a topical or a parenteral route.
23. The use of any one of claims 17-21, wherein the medicament is formulated for subcutaneous administration.
24. The use of any one of claims 17-23, wherein the medicament is formulated for administration once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once every eleven weeks.
25. The use of any one of claims 17-24, wherein the subject is an adult.
26. The use of any one of claims 17-24, wherein the subject is a pediatric patient.
27. The use of any one of claims 17-26, wherein the medicament is formulated for administration by a flat dosing regimen.
28. The use of any one of claims 17-26, wherein the medicament is formulated for administration by a loading dose regimen.
29. The use of any one of claims 17-28, wherein the medicament comprises nemolizumab.
30. The use of any one of claims 17-29, wherein the medicament further comprises an anti-inflammatory drug or an immunosuppressive drug.
31. The use of claim 30, wherein the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID).
32. The use of claim 30, wherein the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.
33. A pharmaceutical composition comprising nemolizumab or an equivalent thereof for treatment of systemic sclerosis in a subject in need, wherein the pharmaceutical composition comprises a dosage of nemolizumab or an equivalent thereof that is (a) at least 30 mg and up to 90 mg nemolizumab or an equivalent thereof when the subject weighs less than 90 kg, or-75- 4915-2894-6601.1Atty. Dkt. No.: 105153-10021(b) at least 60 mg and up to 120 mg nemolizumab or an equivalent thereof when the subject weighs equal to or more than 90 kg.
34. A pharmaceutical composition comprising nemolizumab or an equivalent thereof for treatment of systemic sclerosis, wherein the pharmaceutical composition comprises a dosage of nemolizumab or an equivalent thereof that is at least 70 mg and up to 140 mg nemolizumab or an equivalent thereof.
35. The pharmaceutical composition of claim 33 or 34, wherein the subject suffers from one or more, moderate to severe systemic sclerosis.
36. The pharmaceutical composition of any one of claims 33-35, wherein the systemic sclerosis is a diffuse scleroderma or a limited scleroderma.
37. The pharmaceutical composition of any one of claims 33-36, wherein the systemic sclerosis has been assigned a score of at least 15 on the modified Rodnan skin score (mRSS).
38. The pharmaceutical composition of any one of claims 33-37, wherein the pharmaceutical composition is formulated for administration by a topical or parenteral route.
39. The pharmaceutical composition of any one of claims 33-37, wherein the pharmaceutical composition is formulated for subcutaneous administration.
40. The pharmaceutical composition of any one of claims 33-39, wherein the pharmaceutical composition is formulated for administration once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, once every nine weeks, once every ten weeks, or once every eleven weeks.
41. The pharmaceutical composition of any one of claims 33-40, wherein the subject is an adult.
42. The pharmaceutical composition of any one of claims 33-40, wherein the subject is a pediatric patient.
43. The pharmaceutical composition of any one of claims 33-42, wherein the pharmaceutical composition is formulated for administration by a flat dosing regimen.-76- 4915-2894-6601.1Atty. Dkt. No.: 105153-1002144. The pharmaceutical composition of any one of claims 33-42, wherein the pharmaceutical composition is formulated for administration by a loading dose regimen.
45. The pharmaceutical composition of any one of claims 33-44, wherein the pharmaceutical composition comprises nemolizumab.
46. The pharmaceutical composition of any one of claims 33-45, further comprising an anti-inflammatory drug or an immunosuppressive drug.
47. The pharmaceutical composition of claim 46, wherein the anti-inflammatory drug is selected from a corticosteroid or a nonsteroidal anti-inflammatory drug (NSAID).
48. The pharmaceutical composition of claim 46, wherein the immunosuppressive drug is selected from Rituximab, Tocilizumab, Nintedanib, methotrexate, cyclosporine, antithymocyte globulin, mycophenolate mofetil, or cyclophosphamide.4915-2894-6601.1
